Ameloblastoma

MONDO:0017795 Pathograph 19 Show in embeddings browser odontogenic neoplasm

Ameloblastoma is a rare, usually benign epithelial odontogenic tumor of the jaw that is slow growing but locally invasive and destructive. Most tumors arise in the mandible. Recurrent somatic alterations activate MAPK or Hedgehog signaling, most often through BRAF p.Val600Glu or activating SMO variants. Surgery remains the principal treatment; recurrence risk is higher after conservative procedures, while radical surgery can cause substantial functional and aesthetic morbidity. Molecularly matched therapy is an emerging option for selected recurrent, unresectable, or neoadjuvant cases.

Ask OpenScientist

Ask a research question about Ameloblastoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
2
Histopath.
3
Phenotypes
2
Gaps
19
Pathograph
6
Genes
4
Medical Actions
4
Subtypes
3
Differentials
1
Trials
2
Models
16
References
1
Deep Research
🏷

Classifications

Harrison's Part
ONCOLOGY HEMATOLOGY
◆

Subtypes

4
Conventional ameloblastoma
The intraosseous conventional form includes tumors historically described as solid or multicystic. Conventional classification is a reported risk factor for recurrence.
Show evidence (1 reference)
PMID:39177897 SUPPORT Human Clinical
"The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic)..."
The scoping review directly identifies conventional solid/multicystic ameloblastoma and its association with recurrence.
Unicystic ameloblastoma
A cystic form that can resemble dentigerous cyst or odontogenic keratocyst; mural invasion is associated with recurrence risk.
Show evidence (2 references)
PMID:33897185 SUPPORT Human Clinical
"Unicystic ameloblastoma poses a diagnostic challenge, as its histologic presentation can be sometimes mistaken for cystic odontogenic lesions."
The study directly supports the cystic diagnostic overlap.
PMID:39177897 SUPPORT Human Clinical
"The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic)..."
The review directly identifies mural unicystic histology as a recurrence factor.
Peripheral ameloblastoma
A soft-tissue variant rather than an intraosseous jaw lesion.
Show evidence (1 reference)
PMID:24963238 SUPPORT Human Clinical
"10 cases showed radiographic findings, while one case was a peripheral soft-tissue variant."
This case series directly describes peripheral ameloblastoma as a soft-tissue variant.
Metastasizing ameloblastoma
The rare metastasizing form most often spreads to the lungs, followed by cervical lymph nodes, and has a different clinical profile from ameloblastic carcinoma.
Show evidence (1 reference)
PMID:35822408 SUPPORT Human Clinical
"Metastases mainly affected the lungs, followed by cervical lymph nodes."
The systematic review directly supports the principal metastatic sites.
?

Discussions and Knowledge Gaps

2
How faithfully do current ameloblastoma models predict durable responses in patients?
HUMAN MODEL MISMATCH OPEN ameloblastoma_preclinical_model_fidelity
Attached to
experimental_models#Conditionally reprogrammed human ameloblastoma cell-line panel experimental_models#Fully humanized 3D ameloblastoma-bone coculture treatments#Molecularly Matched Targeted Therapy
Benign ameloblastoma cells have finite proliferation in two-dimensional culture, immortalization may alter phenotype, and subcutaneous xenograft engraftment is inefficient. Current response evidence is encouraging but small, and organoid or humanized models require further validation against long-term clinical outcomes.
Show evidence (1 reference)
PMID:37550047 SUPPORT Other
"In fact, benign tumor cells generally showed a finite proliferative capacity in two-dimensional culture, and most likely, they could exhibit altered cellular phenotype after immortalization. Moreover, this benign tumor presented low chances of subcutaneous engraftment in nude mice."
The review directly states major fidelity and engraftment limitations of current models.
Which patients obtain durable oncologic control from molecularly matched therapy, and when can surgical extent safely be reduced?
KNOWLEDGE GAP OPEN ameloblastoma_targeted_therapy_durability
Attached to
treatments#Molecularly Matched Targeted Therapy pathophysiology#Somatic RTK-RAS-MAPK Driver Alterations
Prospective evidence comprises a small observational cohort. Larger studies with standardized response, recurrence, resistance, and long-term surgical outcome measures are needed before targeted therapy can be treated as routine first-line management.
Show evidence (1 reference)
PMID:42286159 SUPPORT Human Clinical
"This prospective observational study included comprehensive molecular profiling of 14 patients with ameloblastoma."
The study directly establishes the limited prospective cohort size.
⚙

Pathophysiology

6
Somatic RTK-RAS-MAPK Driver Alterations
Recurrent somatic activating variants in BRAF, KRAS, and FGFR2 define a major molecular route in ameloblastoma. BRAF p.Val600Glu is the most common alteration and is enriched in mandibular tumors; HRAS and NRAS alterations are also observed in molecularly profiled tumors or cell lines.
BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. FGFR2 hgnc:3689 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves FGFR2 (hgnc:3689). hgnc:3689 is a gene from the HUGO Gene Nomenclature Committee. KRAS hgnc:6407 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves KRAS (hgnc:6407). hgnc:6407 is a gene from the HUGO Gene Nomenclature Committee. NRAS hgnc:7989 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NRAS (hgnc:7989). hgnc:7989 is a gene from the HUGO Gene Nomenclature Committee. HRAS hgnc:5173 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HRAS (hgnc:5173). hgnc:5173 is a gene from the HUGO Gene Nomenclature Committee.
MAPK cascade GO:0000165 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased MAPK cascade (GO:0000165). GO:0000165 is a biological process from the Gene Ontology. ↑ INCREASED
Experimental models
Conditionally reprogrammed human ameloblastoma cell-line panel CELL LINE The panel models several MAPK-pathway driver genotypes and their inhibitor sensitivity.
Downstream
Oncogenic Odontogenic Epithelial Proliferation Activating RTK-RAS-MAPK alterations promote tumor-cell growth and survival.
Show evidence (3 references)
PMID:24859340 SUPPORT Human Clinical
"Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material."
Genomic analysis directly establishes recurrent oncogenic MAPK-pathway alterations.
PMID:36428683 SUPPORT Human Clinical
"Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."
The meta-analysis quantifies BRAF p.Val600Glu and its mandibular enrichment.
PMID:42286159 SUPPORT Human Clinical
"Pathogenic mutations were identified in all cases, including alterations in BRAF, SMO, HRAS, FGFR2, and PIK3CA."
Prospective profiling directly supports HRAS and FGFR2 alterations in human tumors.
Activating SMO-Hedgehog Signaling
Recurrent activating SMO variants define an alternative Hedgehog-signaling route that is enriched in maxillary ameloblastoma.
SMO hgnc:11119 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SMO (hgnc:11119). hgnc:11119 is a gene from the HUGO Gene Nomenclature Committee.
smoothened signaling pathway GO:0007224 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased smoothened signaling pathway (GO:0007224). GO:0007224 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Oncogenic Odontogenic Epithelial Proliferation Constitutively active SMO promotes proliferation in ameloblast-lineage cells.
Show evidence (1 reference)
PMID:24859340 SUPPORT Human Clinical
"Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible."
The human tumor series directly establishes the site-associated SMO molecular class.
Oncogenic Odontogenic Epithelial Proliferation
Driver-dependent survival and proliferation of ameloblast-lineage tumor cells expands the odontogenic epithelial tumor compartment.
ameloblast CL:0000059 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves ameloblast (CL:0000059). CL:0000059 is a cell type from the Cell Ontology.
positive regulation of epithelial cell proliferation GO:0050679 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of epithelial cell proliferation (GO:0050679). GO:0050679 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
RANKL-Dependent Osteoclast Activation Tumor-stromal signaling promotes osteoclast activation in the ameloblastoma-bone microenvironment.
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
Mutation-matched MEK inhibition functionally demonstrates MAPK dependence in ameloblastoma cells.
RANKL-Dependent Osteoclast Activation
RANKL signaling in the ameloblastoma-bone microenvironment activates osteoclasts; neutralization with denosumab reduces this activation in a fully human in-vitro model.
osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
osteoclast differentiation GO:0030316 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased osteoclast differentiation (GO:0030316). GO:0030316 is a biological process from the Gene Ontology. ↑ INCREASED
Experimental models
Fully humanized 3D ameloblastoma-bone coculture CO CULTURE The coculture assays RANKL release and osteoclast activation in a human tumor-stromal context.
Downstream
Local Jawbone Invasion and Destruction Activated osteoclasts contribute to resorption of jawbone adjacent to tumor.
Show evidence (1 reference)
PMID:36582941 SUPPORT In Vitro
"Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
RANKL neutralization directly reduced osteoclast activation in the human ameloblastoma-bone model.
Local Jawbone Invasion and Destruction
Ameloblastoma invades and destroys jawbone and surrounding structures, producing expansile radiolucent lesions and local mass effects.
bone resorption GO:0045453 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased bone resorption (GO:0045453). GO:0045453 is a biological process from the Gene Ontology. ↑ INCREASED
mandible UBERON:0001684 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in mandible (UBERON:0001684). UBERON:0001684 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Jaw Swelling Expansile tumor growth produces enlargement of the affected jaw.
Tooth Malposition Expansile jaw lesions can displace involved teeth.
Facial Asymmetry Advanced jaw deformity can produce facial asymmetry.
Distant Metastatic Dissemination A rare subset disseminates beyond the primary jaw tumor by mechanisms that remain incompletely defined.
Show evidence (1 reference)
PMID:35689405 SUPPORT Other
"Although relatively uncommon and rarely metastatic, AB tumors are locally invasive and destructive to the jawbone and surrounding structures."
The source directly supports local invasion and jawbone destruction.
Distant Metastatic Dissemination
Metastasizing ameloblastoma most often spreads to lung and then cervical lymph nodes.
lung UBERON:0002048 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lung (UBERON:0002048). UBERON:0002048 is an anatomical location from the Uberon multi-species anatomy ontology. lymph node UBERON:0000029 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lymph node (UBERON:0000029). UBERON:0000029 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:35822408 SUPPORT Human Clinical
"Metastases mainly affected the lungs, followed by cervical lymph nodes."
The systematic review directly establishes the metastatic distribution.
✶

Histopathology

2
Follicular Pattern
Follicular is one of the predominant histopathologic patterns in pooled cases.
Show evidence (1 reference)
PMID:30614154 SUPPORT Human Clinical
"The histopathologic patterns were mostly follicular and plexiform."
The meta-analysis directly identifies follicular histology as a predominant pattern.
Plexiform Pattern
Plexiform is one of the predominant histopathologic patterns in pooled cases.
Show evidence (1 reference)
PMID:30614154 SUPPORT Human Clinical
"The histopathologic patterns were mostly follicular and plexiform."
The meta-analysis directly identifies plexiform histology as a predominant pattern.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Ameloblastoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Head and Neck 1
Facial Asymmetry HP:0000324 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Facial asymmetry (HP:0000324), qualified as course progressive. HP:0000324 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:42286159 SUPPORT Human Clinical
"an advanced size, causing severe jaw deformity, facial asymmetry, and functional impairment."
The source directly names facial asymmetry as a consequence of advanced tumors.
Other 2
Jaw Swelling HP:0030793 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Jaw swelling (HP:0030793), qualified as course progressive. HP:0030793 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:11402276 SUPPORT Human Clinical
"Swelling was the most common symptom and was experienced by 27 (38.0%) patients."
The 71-case clinical series directly supports the phenotype and provides a cohort-specific frequency.
Tooth Malposition HP:0000692 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tooth malposition (HP:0000692). HP:0000692 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24963238 SUPPORT Human Clinical
"Radiographic features that could help in diagnosing ameloblastomas include its predominant occurrence in the mandible, multilocular radiolucency with well-defined, corticated, scalloped margins, expansion of buccal and lingual cortical plates, root resorption and tooth displacement."
The case series directly supports tooth displacement.
🧬

Genetic Associations

6
BRAF
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:36428683 SUPPORT Human Clinical
"Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."
The meta-analysis directly supports frequency and anatomic association.
SMO
Gene: SMO hgnc:11119 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SMO (hgnc:11119). hgnc:11119 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:24859340 SUPPORT Human Clinical
"Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible."
The genomic series directly supports the driver and site association.
FGFR2
Gene: FGFR2 hgnc:3689 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FGFR2 (hgnc:3689). hgnc:3689 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:24859340 SUPPORT Human Clinical
"Additional mutations in the MAPK pathway were also identified, including four cases (15%) with mutation of KRAS (encoding p.Gly12Arg) and five cases (19%) with mutation of FGFR2 (four encoding p.Cys382Arg and one encoding p.Asn549Lys), the presumptive upstream receptor tyrosine kinase."
The human tumor series directly identifies recurrent FGFR2 variants.
KRAS
Gene: KRAS hgnc:6407 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is KRAS (hgnc:6407). hgnc:6407 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:24859340 SUPPORT Human Clinical
"Additional mutations in the MAPK pathway were also identified, including four cases (15%) with mutation of KRAS (encoding p.Gly12Arg) and five cases (19%) with mutation of FGFR2 (four encoding p.Cys382Arg and one encoding p.Asn549Lys), the presumptive upstream receptor tyrosine kinase."
The human tumor series directly identifies recurrent KRAS variants.
NRAS
Gene: NRAS hgnc:7989 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NRAS (hgnc:7989). hgnc:7989 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"we report the establishment of 6 new AB cell lines-generated by "conditional reprogramming"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
Genomic characterization directly identifies NRAS as a driver in ameloblastoma cell lines.
HRAS
Gene: HRAS hgnc:5173 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HRAS (hgnc:5173). hgnc:5173 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:42286159 SUPPORT Human Clinical
"Pathogenic mutations were identified in all cases, including alterations in BRAF, SMO, HRAS, FGFR2, and PIK3CA."
Prospective human tumor profiling directly identifies pathogenic HRAS alterations.
💊

Medical Actions

4
Aggressive Surgical Resection
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Radical or otherwise aggressive resection lowers recurrence compared with conservative surgery but can cause major functional and aesthetic morbidity.
Show evidence (2 references)
PMID:34094934 SUPPORT Human Clinical
"The pooled results indicated that the recurrence rate for aggressive treatment was much lower than that for conservative treatment."
The meta-analysis directly supports lower recurrence after aggressive versus conservative surgery.
PMID:42286159 SUPPORT Human Clinical
"Ameloblastomas are locally aggressive jaw tumors, primarily treated with radical surgery, which often results in significant functional and aesthetic morbidity."
The prospective study directly describes radical surgery as principal treatment and its morbidity.
Conservative Surgical Treatment
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Enucleation, curettage, or marsupialization may preserve jaw structure and quality of life in selected patients but carries a higher recurrence risk and requires closer surveillance.
Show evidence (2 references)
PMID:39274556 SUPPORT Human Clinical
"Despite the high recurrence rate, the latter was more appropriate in the case of smaller lesions and younger patients, due to better post-operative quality of life and reduced functional and esthetic impairments."
The umbrella review directly supports the recurrence-versus-morbidity tradeoff for conservative treatment.
PMID:39177897 SUPPORT Human Clinical
"The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic)..."
The review directly identifies the conservative procedures and their association with recurrence.
Molecularly Matched Targeted Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dabrafenib CHEBI:75045 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dabrafenib (CHEBI:75045). CHEBI:75045 is a therapeutic agent from Chemical Entities of Biological Interest. trametinib CHEBI:75998 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses trametinib (CHEBI:75998). CHEBI:75998 is a therapeutic agent from Chemical Entities of Biological Interest. vemurafenib CHEBI:63637 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vemurafenib (CHEBI:63637). CHEBI:63637 is a therapeutic agent from Chemical Entities of Biological Interest.
BRAF-directed therapy with dabrafenib with or without trametinib is an emerging, molecularly selected option. Evidence now includes prospective observational treatment, but cohort size and long-term disease-control data remain limited; use is not represented here as established first-line care.
Mechanism Target:
INHIBITS Somatic RTK-RAS-MAPK Driver Alterations — Dabrafenib inhibits mutant BRAF and trametinib inhibits downstream MEK signaling.
Show evidence (2 references)
PMID:24859340 SUPPORT In Vitro
"ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib."
Mutation-matched inhibitor sensitivity directly supports inhibition of the BRAF driver mechanism.
PMID:35689405 SUPPORT In Vitro
"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
MEK-inhibitor sensitivity directly supports inhibition of downstream MAPK signaling in ameloblastoma cells.
Show evidence (2 references)
PMID:42286159 SUPPORT Human Clinical
"Personalized treatment recommendations were made for 13 patients, and 11 received matched therapies: dabrafenib ± trametinib (n = 9), futibatinib (n = 1), or binimetinib (n = 1). Radiological tumor regression occurred in 10 of 11 treated patients."
The prospective study directly reports molecularly matched regimens and responses.
PMID:38927880 SUPPORT Human Clinical
"covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes."
The systematic review supports treatment responses while retaining the limitation of a small case-based evidence base.
Experimental SMO-Directed Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Smoothened Antagonist BMS-833923 NCIT:C77861 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Smoothened Antagonist BMS-833923 (NCIT:C77861). NCIT:C77861 is a therapeutic agent from the NCI Thesaurus.
SMO-L412F ameloblastoma cells were resistant to vismodegib but sensitive in vitro to the distinct Smoothened inhibitor BMS-833923. This is preclinical genotype-specific evidence, not an established clinical treatment.
Mechanism Target:
INHIBITS Activating SMO-Hedgehog Signaling — BMS-833923 reduced Hedgehog signaling and viability, whereas SMO-L412F cells were insensitive to vismodegib.
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
The mutation-matched experiment directly supports both vismodegib resistance and BMS-833923 sensitivity.
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
The study directly establishes the genotype-specific preclinical response and resistance pattern.
🔬

Diagnosis

1
Biopsy with histopathologic examination
Clinical and radiologic findings define the lesion and extent, but tissue biopsy is required when ameloblastoma remains in the differential.
biopsy procedure NCIT:C15189 NCI Thesaurus (NCIT)
Results: Histopathology establishes the ameloblastoma diagnosis and subtype.
Show evidence (1 reference)
PMID:11402276 SUPPORT Human Clinical
"When the diagnosis of ameloblastoma in young people remains in doubt after clinical and radiologic examination, a biopsy is necessary."
The clinical series directly supports biopsy after indeterminate clinical and radiologic assessment.
🩻

Imaging Findings

2
Well-demarcated unilocular jaw radiolucency on radiography
A well-demarcated unilocular radiolucent jaw lesion is a common but nonspecific appearance.
Xray
mandible UBERON:0001684 Uberon multi-species anatomy ontology (UBERON)
Show evidence (1 reference)
PMID:11402276 SUPPORT Human Clinical
"Radiographically, 42 (59.2%) of the 71 tumors were unilocular with a well-demarcated border."
The cohort directly quantifies the unilocular, well-demarcated appearance.
Multilocular or soap-bubble jaw radiolucency on radiography
Multilocular radiolucency, sometimes described as soap-bubble, is a supportive but nonspecific appearance.
Xray
mandible UBERON:0001684 Uberon multi-species anatomy ontology (UBERON)
Show evidence (1 reference)
PMID:24963238 SUPPORT Human Clinical
"Seven (70%) of the 10 tumors were multilocular with a well-demarcated corticated border, and three cases (30%) were unilocular. Two cases showed a soap-bubble appearance."
The series directly documents multilocular and soap-bubble appearances.
📈

Progression

2
Local growth and presentation
Age: Any age; peak incidence in the third decade
Tumors are commonly mandibular and may present with swelling and progressive jaw expansion. Mean age in the global meta-analysis was 34 years.
Show evidence (2 references)
PMID:30614154 SUPPORT Human Clinical
"Mean age was 34 years and the peak age incidence in the third decade of life."
The meta-analysis directly supports the age profile.
PMID:11402276 SUPPORT Human Clinical
"Sixty-two (87.3%) of the 71 ameloblastomas were located in the mandible."
The clinical cohort directly supports mandibular predominance.
Post-treatment surveillance and recurrence
Duration: Long-term
Recurrence can follow surgery, particularly conservative treatment; regular long-term follow-up is therefore important.
Show evidence (2 references)
PMID:11402276 SUPPORT Human Clinical
"The overall recurrence rate was 21.1%, and the average age of the patient at recurrence was 26.4 years."
The cohort directly documents post-treatment recurrence.
PMID:11402276 SUPPORT Human Clinical
"Long-term follow-up at regular intervals after surgery is also recommended."
The authors directly recommend long-term postoperative surveillance.
📊

Prevalence

1
Global estimate based on studies from Europe, Africa, and Australia
Annual Incidence 0.092 per 100,000 (0.057–0.149)
Pooled incidence was 0.92 per million person-years (95% CI 0.57-1.49), equivalent to 0.092 per 100,000 person-years; heterogeneity was significant and the included studies did not provide worldwide geographic coverage.
Show evidence (1 reference)
PMID:30614154 SUPPORT Human Clinical
"The pooled incidence rate was 0.92 per million person-years (95% CI: 0.57-1.49), with significant heterogeneity between studies."
The meta-analysis directly provides the pooled rate, confidence interval, and heterogeneity limitation.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Ameloblastoma:

Dentigerous cyst
Overlapping Features A cystic odontogenic lesion that can overlap histologically with unicystic ameloblastoma.
Distinguishing Features
  • Calretinin staining was absent in the dentigerous cyst cases but present in most ameloblastoma and unicystic ameloblastoma cases in one study.
Show evidence (1 reference)
PMID:33897185 SUPPORT Human Clinical
"All the cases of OKC and dentigerous cyst were negative for calretinin."
The study directly supports a histopathologic adjunct distinguishing the cyst from ameloblastoma.
Odontogenic keratocyst
Overlapping Features A cystic odontogenic lesion included in the histopathologic differential of unicystic ameloblastoma.
Distinguishing Features
  • Calretinin staining was absent in the odontogenic keratocyst cases but present in most ameloblastoma and unicystic ameloblastoma cases in one study.
Show evidence (2 references)
PMID:33897185 SUPPORT Human Clinical
"A total of eighty cases, in which twenty cases each of ameloblastoma, unicystic ameloblastoma, dentigerous cyst, and odontogenic keratocyst (OKC) were included in the study."
The comparison directly places odontogenic keratocyst in the studied differential.
PMID:33897185 SUPPORT Human Clinical
"All the cases of OKC and dentigerous cyst were negative for calretinin."
The study directly supports calretinin as a distinguishing adjunct.
Ameloblastic carcinoma
Overlapping Features A malignant odontogenic tumor that must not be conflated with metastasizing ameloblastoma; the two have distinct clinical profiles and outcomes.
Distinguishing Features
  • Ameloblastic carcinoma has worse survival after metastasis than metastasizing ameloblastoma in the systematic review.
Show evidence (1 reference)
PMID:35822408 SUPPORT Human Clinical
"Considering only the cases that metastasized, a higher ratio of AC patients died in comparison to MA patients (p = 0.003)."
The systematic review directly distinguishes prognostic behavior after metastasis.
🔬

Clinical Trials

1
NCT02367859 dabrafenib plus trametinib pilot study
Pilot study of dabrafenib and trametinib for BRAF-mutated ameloblastoma.
Show evidence (1 reference)
clinicaltrials:NCT02367859 SUPPORT Human Clinical
"This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene."
The registry directly supports the molecularly selected ameloblastoma trial.
🧫

Experimental Models

2
Conditionally reprogrammed human ameloblastoma cell-line panel CELL_LINE
Six newly established ameloblastoma cell lines with characterized oncogenic drivers support mutation-matched drug testing.
FGFR2-, KRAS-, NRAS-, BRAF-, PIK3CA-, or SMO-altered ameloblastoma cells
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Human ameloblastoma tumor cells generated by conditional reprogramming
Culture
Conditionally reprogrammed cell culture
Publication
PMID:35689405
Pathograph links
Somatic RTK-RAS-MAPK Driver Alterations The panel models several MAPK-pathway driver genotypes and their inhibitor sensitivity.
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"we report the establishment of 6 new AB cell lines-generated by "conditional reprogramming"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
The paper directly describes the model panel and its genotypes.
Findings
KRAS- or NRAS-mutant cells were highly sensitive to MEK inhibition.
"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
The cell-line perturbation directly supports the finding.
Show evidence (1 reference)
PMID:35689405 SUPPORT In Vitro
"we report the establishment of 6 new AB cell lines-generated by "conditional reprogramming"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
The source directly establishes the panel.
Fully humanized 3D ameloblastoma-bone coculture CO_CULTURE
A dense-collagen model combining human osteoblasts, activated human osteoclasts, and AM-1 or AM-3 ameloblastoma cells.
Untreated human ameloblastoma-bone coculture Denosumab-treated human ameloblastoma-bone coculture
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Human osteoblasts, CD14-positive monocyte-derived osteoclasts, and AM-1/AM-3 ameloblastoma cell lines
Culture
Three-dimensional dense collagen type I matrix with engineered bone-like nodules
Publication
PMID:36582941
Pathograph links
RANKL-Dependent Osteoclast Activation The coculture assays RANKL release and osteoclast activation in a human tumor-stromal context.
Show evidence (1 reference)
PMID:36582941 SUPPORT In Vitro
"The aim of this study was to recapitulate ameloblastoma in a completely humanised 3D disease model containing ameloblastoma cells, osteoblasts and activated osteoclasts to investigate the RANKL pathway within the ameloblastoma stromal environment and its response to the RANKL antibody denosumab."
The source directly defines the model and the mechanism it assays.
Findings
Denosumab reduced osteoclast activation in the presence of osteoblasts and ameloblastoma cells.
"Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
Show evidence (1 reference)
PMID:36582941 SUPPORT In Vitro
"Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
The intervention directly supports RANKL-dependent osteoclast activation in the model.
Show evidence (1 reference)
PMID:36582941 SUPPORT In Vitro
"Lastly, the ameloblastoma cell lines AM-1 and AM-3 were incorporated into the 3D model."
The source directly identifies the ameloblastoma cell lines used in the 3D model.
{ }

Source YAML

click to show 
name: Ameloblastoma
creation_date: "2026-06-22T00:00:00Z"
description: >-
  Ameloblastoma is a rare, usually benign epithelial odontogenic tumor of the
  jaw that is slow growing but locally invasive and destructive. Most tumors
  arise in the mandible. Recurrent somatic alterations activate MAPK or
  Hedgehog signaling, most often through BRAF p.Val600Glu or activating SMO
  variants. Surgery remains the principal treatment; recurrence risk is higher
  after conservative procedures, while radical surgery can cause substantial
  functional and aesthetic morbidity. Molecularly matched therapy is an
  emerging option for selected recurrent, unresectable, or neoadjuvant cases.
categories:
- Odontogenic Tumor
- Benign Neoplasm
parents:
- odontogenic neoplasm
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:42286159
      reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ameloblastomas are locally aggressive jaw tumors, primarily treated with radical surgery, which often results in significant functional and aesthetic morbidity."
      explanation: The disease is directly characterized as a tumor treated within an oncologic surgical framework.
disease_term:
  preferred_term: ameloblastoma
  term:
    id: MONDO:0017795
    label: ameloblastoma
has_subtypes:
- name: Conventional
  display_name: Conventional ameloblastoma
  description: >-
    The intraosseous conventional form includes tumors historically described
    as solid or multicystic. Conventional classification is a reported risk
    factor for recurrence.
  evidence:
  - reference: PMID:39177897
    reference_title: "Factors Associated with Recurrence of Ameloblastoma: A Scoping Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic) ameloblastoma, (7) histological subtype - mural invasion of unicystic ameloblastoma, (8) conservative treatment modalities - simple enucleation, curettage, and marsupialization, and (9) non-extraction/preservation of involved teeth."
    explanation: The scoping review directly identifies conventional solid/multicystic ameloblastoma and its association with recurrence.
- name: Unicystic
  display_name: Unicystic ameloblastoma
  description: >-
    A cystic form that can resemble dentigerous cyst or odontogenic keratocyst;
    mural invasion is associated with recurrence risk.
  evidence:
  - reference: PMID:33897185
    reference_title: "Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unicystic ameloblastoma poses a diagnostic challenge, as its histologic presentation can be sometimes mistaken for cystic odontogenic lesions."
    explanation: The study directly supports the cystic diagnostic overlap.
  - reference: PMID:39177897
    reference_title: "Factors Associated with Recurrence of Ameloblastoma: A Scoping Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic) ameloblastoma, (7) histological subtype - mural invasion of unicystic ameloblastoma, (8) conservative treatment modalities - simple enucleation, curettage, and marsupialization, and (9) non-extraction/preservation of involved teeth."
    explanation: The review directly identifies mural unicystic histology as a recurrence factor.
- name: Peripheral
  display_name: Peripheral ameloblastoma
  description: A soft-tissue variant rather than an intraosseous jaw lesion.
  evidence:
  - reference: PMID:24963238
    reference_title: "Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "10 cases showed radiographic findings, while one case was a peripheral soft-tissue variant."
    explanation: This case series directly describes peripheral ameloblastoma as a soft-tissue variant.
- name: Metastasizing
  display_name: Metastasizing ameloblastoma
  description: >-
    The rare metastasizing form most often spreads to the lungs, followed by
    cervical lymph nodes, and has a different clinical profile from
    ameloblastic carcinoma.
  evidence:
  - reference: PMID:35822408
    reference_title: "Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Metastases mainly affected the lungs, followed by cervical lymph nodes."
    explanation: The systematic review directly supports the principal metastatic sites.

prevalence:
- population: Global estimate based on studies from Europe, Africa, and Australia
  measure_type: ANNUAL_INCIDENCE
  rate_per_100000: 0.092
  rate_low: 0.057
  rate_high: 0.149
  notes: >-
    Pooled incidence was 0.92 per million person-years (95% CI 0.57-1.49),
    equivalent to 0.092 per 100,000 person-years; heterogeneity was significant
    and the included studies did not provide worldwide geographic coverage.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled incidence rate was 0.92 per million person-years (95% CI: 0.57-1.49), with significant heterogeneity between studies."
    explanation: The meta-analysis directly provides the pooled rate, confidence interval, and heterogeneity limitation.

progression:
- phase: Local growth and presentation
  age_range: Any age; peak incidence in the third decade
  notes: >-
    Tumors are commonly mandibular and may present with swelling and progressive
    jaw expansion. Mean age in the global meta-analysis was 34 years.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean age was 34 years and the peak age incidence in the third decade of life."
    explanation: The meta-analysis directly supports the age profile.
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixty-two (87.3%) of the 71 ameloblastomas were located in the mandible."
    explanation: The clinical cohort directly supports mandibular predominance.
- phase: Post-treatment surveillance and recurrence
  duration: Long-term
  notes: >-
    Recurrence can follow surgery, particularly conservative treatment; regular
    long-term follow-up is therefore important.
  evidence:
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The overall recurrence rate was 21.1%, and the average age of the patient at recurrence was 26.4 years."
    explanation: The cohort directly documents post-treatment recurrence.
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Long-term follow-up at regular intervals after surgery is also recommended."
    explanation: The authors directly recommend long-term postoperative surveillance.

pathophysiology:
- name: Somatic RTK-RAS-MAPK Driver Alterations
  biological_scale: MOLECULAR
  conforms_to: sustaining_proliferative_signaling#Oncogenic Growth-Signal Lesion
  description: >-
    Recurrent somatic activating variants in BRAF, KRAS, and FGFR2 define a
    major molecular route in ameloblastoma. BRAF p.Val600Glu is the most common
    alteration and is enriched in mandibular tumors; HRAS and NRAS alterations
    are also observed in molecularly profiled tumors or cell lines.
  genes:
  - preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  - preferred_term: FGFR2
    term:
      id: hgnc:3689
      label: FGFR2
  - preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  - preferred_term: NRAS
    term:
      id: hgnc:7989
      label: NRAS
  - preferred_term: HRAS
    term:
      id: hgnc:5173
      label: HRAS
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  evidence:
  - reference: PMID:24859340
    reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material."
    explanation: Genomic analysis directly establishes recurrent oncogenic MAPK-pathway alterations.
  - reference: PMID:36428683
    reference_title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."
    explanation: The meta-analysis quantifies BRAF p.Val600Glu and its mandibular enrichment.
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic mutations were identified in all cases, including alterations in BRAF, SMO, HRAS, FGFR2, and PIK3CA."
    explanation: Prospective profiling directly supports HRAS and FGFR2 alterations in human tumors.
  downstream:
  - target: Oncogenic Odontogenic Epithelial Proliferation
    description: Activating RTK-RAS-MAPK alterations promote tumor-cell growth and survival.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - MEK and ERK activation
    evidence:
    - reference: PMID:24859340
      reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib."
      explanation: Selective inhibitor sensitivity functionally supports dependence of BRAF-mutant ameloblastoma cells on the activating driver.
- name: Activating SMO-Hedgehog Signaling
  biological_scale: MOLECULAR
  description: >-
    Recurrent activating SMO variants define an alternative Hedgehog-signaling
    route that is enriched in maxillary ameloblastoma.
  genes:
  - preferred_term: SMO
    term:
      id: hgnc:11119
      label: SMO
  biological_processes:
  - preferred_term: smoothened signaling pathway
    modifier: INCREASED
    term:
      id: GO:0007224
      label: smoothened signaling pathway
  evidence:
  - reference: PMID:24859340
    reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible."
    explanation: The human tumor series directly establishes the site-associated SMO molecular class.
  downstream:
  - target: Oncogenic Odontogenic Epithelial Proliferation
    description: Constitutively active SMO promotes proliferation in ameloblast-lineage cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24859340
      reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Notably, overexpression of SMO Leu412Phe in immortalized mouse ameloblast-lineage cells (the ALC line10) enhanced cell proliferation in comparison to overexpression of wild-type SMO or empty vector control (Fig. 3), demonstrating a relevant phenotype in a germane cell type."
      explanation: The perturbation directly links activating SMO to increased ameloblast-lineage proliferation.
- name: Oncogenic Odontogenic Epithelial Proliferation
  biological_scale: CELLULAR
  conforms_to: sustaining_proliferative_signaling#Growth-Factor-Independent Proliferation
  description: >-
    Driver-dependent survival and proliferation of ameloblast-lineage tumor cells
    expands the odontogenic epithelial tumor compartment.
  cell_types:
  - preferred_term: ameloblast
    term:
      id: CL:0000059
      label: ameloblast
  biological_processes:
  - preferred_term: positive regulation of epithelial cell proliferation
    modifier: INCREASED
    term:
      id: GO:0050679
      label: positive regulation of epithelial cell proliferation
  evidence:
  - reference: PMID:35689405
    reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
    explanation: Mutation-matched MEK inhibition functionally demonstrates MAPK dependence in ameloblastoma cells.
  downstream:
  - target: RANKL-Dependent Osteoclast Activation
    description: Tumor-stromal signaling promotes osteoclast activation in the ameloblastoma-bone microenvironment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - RANKL release from tumor-stromal coculture
    evidence:
    - reference: PMID:36582941
      reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "RANKL release was validated through TACE/ADAM17 activation chemically or through hOB co-culture."
      explanation: The human 3D coculture directly demonstrates RANKL release in the modeled tumor-stromal context.
- name: RANKL-Dependent Osteoclast Activation
  biological_scale: CELLULAR
  description: >-
    RANKL signaling in the ameloblastoma-bone microenvironment activates
    osteoclasts; neutralization with denosumab reduces this activation in a
    fully human in-vitro model.
  cell_types:
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  biological_processes:
  - preferred_term: osteoclast differentiation
    modifier: INCREASED
    term:
      id: GO:0030316
      label: osteoclast differentiation
  evidence:
  - reference: PMID:36582941
    reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
    explanation: RANKL neutralization directly reduced osteoclast activation in the human ameloblastoma-bone model.
  downstream:
  - target: Local Jawbone Invasion and Destruction
    description: Activated osteoclasts contribute to resorption of jawbone adjacent to tumor.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Osteoclast-mediated bone resorption
    evidence:
    - reference: PMID:36582941
      reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The aim of this study was to recapitulate ameloblastoma in a completely humanised 3D disease model containing ameloblastoma cells, osteoblasts and activated osteoclasts to investigate the RANKL pathway within the ameloblastoma stromal environment and its response to the RANKL antibody denosumab."
      explanation: The model supports the proposed osteoclast-mediated bridge, but it does not directly measure patient jawbone invasion; the edge is therefore partial and indirect.
- name: Local Jawbone Invasion and Destruction
  biological_scale: TISSUE
  description: >-
    Ameloblastoma invades and destroys jawbone and surrounding structures,
    producing expansile radiolucent lesions and local mass effects.
  locations:
  - preferred_term: mandible
    term:
      id: UBERON:0001684
      label: mandible
  biological_processes:
  - preferred_term: bone resorption
    modifier: INCREASED
    term:
      id: GO:0045453
      label: bone resorption
  evidence:
  - reference: PMID:35689405
    reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Although relatively uncommon and rarely metastatic, AB tumors are locally invasive and destructive to the jawbone and surrounding structures."
    explanation: The source directly supports local invasion and jawbone destruction.
  downstream:
  - target: Jaw Swelling
    description: Expansile tumor growth produces enlargement of the affected jaw.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11402276
      reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Swelling was the most common symptom and was experienced by 27 (38.0%) patients."
      explanation: The clinical series directly documents jaw swelling in ameloblastoma.
  - target: Tooth Malposition
    description: Expansile jaw lesions can displace involved teeth.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24963238
      reference_title: "Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Radiographic features that could help in diagnosing ameloblastomas include its predominant occurrence in the mandible, multilocular radiolucency with well-defined, corticated, scalloped margins, expansion of buccal and lingual cortical plates, root resorption and tooth displacement."
      explanation: The case series directly links expanding ameloblastoma lesions with tooth displacement.
  - target: Facial Asymmetry
    description: Advanced jaw deformity can produce facial asymmetry.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Progressive jaw deformity
    evidence:
    - reference: PMID:42286159
      reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an advanced size, causing severe jaw deformity, facial asymmetry, and functional impairment."
      explanation: The clinical paper directly links advanced tumor size and jaw deformity to facial asymmetry.
  - target: Distant Metastatic Dissemination
    description: A rare subset disseminates beyond the primary jaw tumor by mechanisms that remain incompletely defined.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35822408
      reference_title: "Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Metastases mainly affected the lungs, followed by cervical lymph nodes."
      explanation: The systematic review establishes distant dissemination and its sites, but does not resolve the causal intermediates from local invasion.
- name: Distant Metastatic Dissemination
  biological_scale: TISSUE
  subtypes:
  - Metastasizing
  description: Metastasizing ameloblastoma most often spreads to lung and then cervical lymph nodes.
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  evidence:
  - reference: PMID:35822408
    reference_title: "Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Metastases mainly affected the lungs, followed by cervical lymph nodes."
    explanation: The systematic review directly establishes the metastatic distribution.

phenotypes:
- name: Jaw Swelling
  category: Phenotypic
  description: Enlargement of the maxilla or mandible caused by the expansile jaw tumor.
  phenotype_term:
    preferred_term: Jaw swelling
    term:
      id: HP:0030793
      label: Jaw swelling
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Swelling was the most common symptom and was experienced by 27 (38.0%) patients."
    explanation: The 71-case clinical series directly supports the phenotype and provides a cohort-specific frequency.
- name: Tooth Malposition
  category: Phenotypic
  description: Displacement of teeth adjacent to an expansile ameloblastoma.
  phenotype_term:
    preferred_term: Tooth malposition
    term:
      id: HP:0000692
      label: Tooth malposition
  evidence:
  - reference: PMID:24963238
    reference_title: "Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiographic features that could help in diagnosing ameloblastomas include its predominant occurrence in the mandible, multilocular radiolucency with well-defined, corticated, scalloped margins, expansion of buccal and lingual cortical plates, root resorption and tooth displacement."
    explanation: The case series directly supports tooth displacement.
- name: Facial Asymmetry
  category: Phenotypic
  description: Unequal facial contour caused by advanced jaw deformity.
  phenotype_term:
    preferred_term: Facial asymmetry
    term:
      id: HP:0000324
      label: Facial asymmetry
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an advanced size, causing severe jaw deformity, facial asymmetry, and functional impairment."
    explanation: The source directly names facial asymmetry as a consequence of advanced tumors.

histopathology:
- name: Follicular Pattern
  finding_term:
    preferred_term: Follicular ameloblastoma
    term:
      id: NCIT:C27397
      label: Follicular Ameloblastoma
  description: Follicular is one of the predominant histopathologic patterns in pooled cases.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The histopathologic patterns were mostly follicular and plexiform."
    explanation: The meta-analysis directly identifies follicular histology as a predominant pattern.
- name: Plexiform Pattern
  finding_term:
    preferred_term: Plexiform ameloblastoma
    term:
      id: NCIT:C39753
      label: Plexiform Ameloblastoma
  description: Plexiform is one of the predominant histopathologic patterns in pooled cases.
  evidence:
  - reference: PMID:30614154
    reference_title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The histopathologic patterns were mostly follicular and plexiform."
    explanation: The meta-analysis directly identifies plexiform histology as a predominant pattern.

imaging_findings:
- name: Well-demarcated unilocular jaw radiolucency on radiography
  modality: XRAY
  description: A well-demarcated unilocular radiolucent jaw lesion is a common but nonspecific appearance.
  located_in:
    preferred_term: mandible
    term:
      id: UBERON:0001684
      label: mandible
  diagnostic: false
  evidence:
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Radiographically, 42 (59.2%) of the 71 tumors were unilocular with a well-demarcated border."
    explanation: The cohort directly quantifies the unilocular, well-demarcated appearance.
- name: Multilocular or soap-bubble jaw radiolucency on radiography
  modality: XRAY
  description: Multilocular radiolucency, sometimes described as soap-bubble, is a supportive but nonspecific appearance.
  located_in:
    preferred_term: mandible
    term:
      id: UBERON:0001684
      label: mandible
  diagnostic: false
  evidence:
  - reference: PMID:24963238
    reference_title: "Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seven (70%) of the 10 tumors were multilocular with a well-demarcated corticated border, and three cases (30%) were unilocular. Two cases showed a soap-bubble appearance."
    explanation: The series directly documents multilocular and soap-bubble appearances.

genetic:
- name: BRAF
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  notes: Somatic BRAF p.Val600Glu is the most frequent molecular driver and is enriched in mandibular tumors.
  evidence:
  - reference: PMID:36428683
    reference_title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis prevalence of BRAF V600E in ameloblastoma was 70.49%, and a significant meta-analysis association was reported for those younger than 54 years old and in the mandible."
    explanation: The meta-analysis directly supports frequency and anatomic association.
- name: SMO
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: SMO
    term:
      id: hgnc:11119
      label: SMO
  notes: Activating SMO variants are a Hedgehog-pathway driver enriched in maxillary tumors.
  evidence:
  - reference: PMID:24859340
    reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible."
    explanation: The genomic series directly supports the driver and site association.
- name: FGFR2
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: FGFR2
    term:
      id: hgnc:3689
      label: FGFR2
  evidence:
  - reference: PMID:24859340
    reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional mutations in the MAPK pathway were also identified, including four cases (15%) with mutation of KRAS (encoding p.Gly12Arg) and five cases (19%) with mutation of FGFR2 (four encoding p.Cys382Arg and one encoding p.Asn549Lys), the presumptive upstream receptor tyrosine kinase."
    explanation: The human tumor series directly identifies recurrent FGFR2 variants.
- name: KRAS
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  evidence:
  - reference: PMID:24859340
    reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional mutations in the MAPK pathway were also identified, including four cases (15%) with mutation of KRAS (encoding p.Gly12Arg) and five cases (19%) with mutation of FGFR2 (four encoding p.Cys382Arg and one encoding p.Asn549Lys), the presumptive upstream receptor tyrosine kinase."
    explanation: The human tumor series directly identifies recurrent KRAS variants.
- name: NRAS
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: NRAS
    term:
      id: hgnc:7989
      label: NRAS
  evidence:
  - reference: PMID:35689405
    reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we report the establishment of 6 new AB cell lines-generated by \"conditional reprogramming\"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
    explanation: Genomic characterization directly identifies NRAS as a driver in ameloblastoma cell lines.
- name: HRAS
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  gene_term:
    preferred_term: HRAS
    term:
      id: hgnc:5173
      label: HRAS
  evidence:
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic mutations were identified in all cases, including alterations in BRAF, SMO, HRAS, FGFR2, and PIK3CA."
    explanation: Prospective human tumor profiling directly identifies pathogenic HRAS alterations.

diagnosis:
- name: Biopsy with histopathologic examination
  diagnosis_term:
    preferred_term: biopsy procedure
    term:
      id: NCIT:C15189
      label: Biopsy Procedure
  description: >-
    Clinical and radiologic findings define the lesion and extent, but tissue
    biopsy is required when ameloblastoma remains in the differential.
  results: Histopathology establishes the ameloblastoma diagnosis and subtype.
  evidence:
  - reference: PMID:11402276
    reference_title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When the diagnosis of ameloblastoma in young people remains in doubt after clinical and radiologic examination, a biopsy is necessary."
    explanation: The clinical series directly supports biopsy after indeterminate clinical and radiologic assessment.

differential_diagnoses:
- name: Dentigerous cyst
  description: A cystic odontogenic lesion that can overlap histologically with unicystic ameloblastoma.
  distinguishing_features:
  - Calretinin staining was absent in the dentigerous cyst cases but present in most ameloblastoma and unicystic ameloblastoma cases in one study.
  evidence:
  - reference: PMID:33897185
    reference_title: "Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All the cases of OKC and dentigerous cyst were negative for calretinin."
    explanation: The study directly supports a histopathologic adjunct distinguishing the cyst from ameloblastoma.
- name: Odontogenic keratocyst
  description: A cystic odontogenic lesion included in the histopathologic differential of unicystic ameloblastoma.
  distinguishing_features:
  - Calretinin staining was absent in the odontogenic keratocyst cases but present in most ameloblastoma and unicystic ameloblastoma cases in one study.
  evidence:
  - reference: PMID:33897185
    reference_title: "Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of eighty cases, in which twenty cases each of ameloblastoma, unicystic ameloblastoma, dentigerous cyst, and odontogenic keratocyst (OKC) were included in the study."
    explanation: The comparison directly places odontogenic keratocyst in the studied differential.
  - reference: PMID:33897185
    reference_title: "Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All the cases of OKC and dentigerous cyst were negative for calretinin."
    explanation: The study directly supports calretinin as a distinguishing adjunct.
- name: Ameloblastic carcinoma
  description: >-
    A malignant odontogenic tumor that must not be conflated with metastasizing
    ameloblastoma; the two have distinct clinical profiles and outcomes.
  distinguishing_features:
  - Ameloblastic carcinoma has worse survival after metastasis than metastasizing ameloblastoma in the systematic review.
  evidence:
  - reference: PMID:35822408
    reference_title: "Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Considering only the cases that metastasized, a higher ratio of AC patients died in comparison to MA patients (p = 0.003)."
    explanation: The systematic review directly distinguishes prognostic behavior after metastasis.

treatments:
- name: Aggressive Surgical Resection
  description: >-
    Radical or otherwise aggressive resection lowers recurrence compared with
    conservative surgery but can cause major functional and aesthetic morbidity.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:34094934
    reference_title: "Recurrence Rates of Intraosseous Ameloblastoma Cases With Conservative or Aggressive Treatment: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled results indicated that the recurrence rate for aggressive treatment was much lower than that for conservative treatment."
    explanation: The meta-analysis directly supports lower recurrence after aggressive versus conservative surgery.
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ameloblastomas are locally aggressive jaw tumors, primarily treated with radical surgery, which often results in significant functional and aesthetic morbidity."
    explanation: The prospective study directly describes radical surgery as principal treatment and its morbidity.
- name: Conservative Surgical Treatment
  description: >-
    Enucleation, curettage, or marsupialization may preserve jaw structure and
    quality of life in selected patients but carries a higher recurrence risk
    and requires closer surveillance.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:39274556
    reference_title: "The Effect of Conservative vs. Radical Treatment of Ameloblastoma on Recurrence Rate and Quality of Life: An Umbrella Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite the high recurrence rate, the latter was more appropriate in the case of smaller lesions and younger patients, due to better post-operative quality of life and reduced functional and esthetic impairments."
    explanation: The umbrella review directly supports the recurrence-versus-morbidity tradeoff for conservative treatment.
  - reference: PMID:39177897
    reference_title: "Factors Associated with Recurrence of Ameloblastoma: A Scoping Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic) ameloblastoma, (7) histological subtype - mural invasion of unicystic ameloblastoma, (8) conservative treatment modalities - simple enucleation, curettage, and marsupialization, and (9) non-extraction/preservation of involved teeth."
    explanation: The review directly identifies the conservative procedures and their association with recurrence.
- name: Molecularly Matched Targeted Therapy
  description: >-
    BRAF-directed therapy with dabrafenib with or without trametinib is an
    emerging, molecularly selected option. Evidence now includes prospective
    observational treatment, but cohort size and long-term disease-control data
    remain limited; use is not represented here as established first-line care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dabrafenib
      term:
        id: CHEBI:75045
        label: dabrafenib
    - preferred_term: trametinib
      term:
        id: CHEBI:75998
        label: trametinib
    - preferred_term: vemurafenib
      term:
        id: CHEBI:63637
        label: vemurafenib
  target_mechanisms:
  - target: Somatic RTK-RAS-MAPK Driver Alterations
    treatment_effect: INHIBITS
    description: Dabrafenib inhibits mutant BRAF and trametinib inhibits downstream MEK signaling.
    evidence:
    - reference: PMID:24859340
      reference_title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib."
      explanation: Mutation-matched inhibitor sensitivity directly supports inhibition of the BRAF driver mechanism.
    - reference: PMID:35689405
      reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
      explanation: MEK-inhibitor sensitivity directly supports inhibition of downstream MAPK signaling in ameloblastoma cells.
  evidence:
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Personalized treatment recommendations were made for 13 patients, and 11 received matched therapies: dabrafenib ± trametinib (n = 9), futibatinib (n = 1), or binimetinib (n = 1). Radiological tumor regression occurred in 10 of 11 treated patients."
    explanation: The prospective study directly reports molecularly matched regimens and responses.
  - reference: PMID:38927880
    reference_title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes."
    explanation: The systematic review supports treatment responses while retaining the limitation of a small case-based evidence base.
- name: Experimental SMO-Directed Therapy
  description: >-
    SMO-L412F ameloblastoma cells were resistant to vismodegib but sensitive in
    vitro to the distinct Smoothened inhibitor BMS-833923. This is preclinical
    genotype-specific evidence, not an established clinical treatment.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Smoothened Antagonist BMS-833923
      term:
        id: NCIT:C77861
        label: Smoothened Antagonist BMS-833923
  target_mechanisms:
  - target: Activating SMO-Hedgehog Signaling
    treatment_effect: INHIBITS
    description: BMS-833923 reduced Hedgehog signaling and viability, whereas SMO-L412F cells were insensitive to vismodegib.
    evidence:
    - reference: PMID:35689405
      reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
      explanation: The mutation-matched experiment directly supports both vismodegib resistance and BMS-833923 sensitivity.
  evidence:
  - reference: PMID:35689405
    reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AB cells with activating SMO-L412F mutation (Hedgehog pathway) are insensitive to vismodegib; however, a distinct small-molecule SMO inhibitor, BMS-833923, significantly reduces both downstream Hedgehog signaling and tumor cell viability."
    explanation: The study directly establishes the genotype-specific preclinical response and resistance pattern.

clinical_trials:
- name: NCT02367859 dabrafenib plus trametinib pilot study
  description: Pilot study of dabrafenib and trametinib for BRAF-mutated ameloblastoma.
  notes: The available registry evidence establishes the molecularly selected pilot study but does not establish its phase, recruitment status, enrollment, or results.
  evidence:
  - reference: clinicaltrials:NCT02367859
    reference_title: A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene."
    explanation: The registry directly supports the molecularly selected ameloblastoma trial.

experimental_models:
- name: Conditionally reprogrammed human ameloblastoma cell-line panel
  description: Six newly established ameloblastoma cell lines with characterized oncogenic drivers support mutation-matched drug testing.
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Human ameloblastoma tumor cells generated by conditional reprogramming
  culture_system: Conditionally reprogrammed cell culture
  publication: PMID:35689405
  conditions:
  - FGFR2-, KRAS-, NRAS-, BRAF-, PIK3CA-, or SMO-altered ameloblastoma cells
  modeled_mechanisms:
  - target: Somatic RTK-RAS-MAPK Driver Alterations
    description: The panel models several MAPK-pathway driver genotypes and their inhibitor sensitivity.
    evidence:
    - reference: PMID:35689405
      reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we report the establishment of 6 new AB cell lines-generated by \"conditional reprogramming\"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
      explanation: The paper directly describes the model panel and its genotypes.
  findings:
  - statement: KRAS- or NRAS-mutant cells were highly sensitive to MEK inhibition.
    supporting_text: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
    evidence:
    - reference: PMID:35689405
      reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "AB cells with KRAS or NRAS mutation (MAPK pathway) are exquisitely sensitive to MEK inhibition, which propels ameloblast differentiation."
      explanation: The cell-line perturbation directly supports the finding.
  evidence:
  - reference: PMID:35689405
    reference_title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we report the establishment of 6 new AB cell lines-generated by \"conditional reprogramming\"-and their genomic characterization that reveals driver mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO."
    explanation: The source directly establishes the panel.
- name: Fully humanized 3D ameloblastoma-bone coculture
  description: A dense-collagen model combining human osteoblasts, activated human osteoclasts, and AM-1 or AM-3 ameloblastoma cells.
  experimental_model_type: CO_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Human osteoblasts, CD14-positive monocyte-derived osteoclasts, and AM-1/AM-3 ameloblastoma cell lines
  culture_system: Three-dimensional dense collagen type I matrix with engineered bone-like nodules
  publication: PMID:36582941
  conditions:
  - Untreated human ameloblastoma-bone coculture
  - Denosumab-treated human ameloblastoma-bone coculture
  modeled_mechanisms:
  - target: RANKL-Dependent Osteoclast Activation
    description: The coculture assays RANKL release and osteoclast activation in a human tumor-stromal context.
    evidence:
    - reference: PMID:36582941
      reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The aim of this study was to recapitulate ameloblastoma in a completely humanised 3D disease model containing ameloblastoma cells, osteoblasts and activated osteoclasts to investigate the RANKL pathway within the ameloblastoma stromal environment and its response to the RANKL antibody denosumab."
      explanation: The source directly defines the model and the mechanism it assays.
  findings:
  - statement: Denosumab reduced osteoclast activation in the presence of osteoblasts and ameloblastoma cells.
    supporting_text: "Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
    evidence:
    - reference: PMID:36582941
      reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Denosumab treatment resulted in decreased osteoclast activation in the presence of hOB and ameloblastoma cells."
      explanation: The intervention directly supports RANKL-dependent osteoclast activation in the model.
  evidence:
  - reference: PMID:36582941
    reference_title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Lastly, the ameloblastoma cell lines AM-1 and AM-3 were incorporated into the 3D model."
    explanation: The source directly identifies the ameloblastoma cell lines used in the 3D model.

discussions:
- discussion_id: ameloblastoma_preclinical_model_fidelity
  prompt: How faithfully do current ameloblastoma models predict durable responses in patients?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - experimental_models#Conditionally reprogrammed human ameloblastoma cell-line panel
  - experimental_models#Fully humanized 3D ameloblastoma-bone coculture
  - treatments#Molecularly Matched Targeted Therapy
  rationale: >-
    Benign ameloblastoma cells have finite proliferation in two-dimensional
    culture, immortalization may alter phenotype, and subcutaneous xenograft
    engraftment is inefficient. Current response evidence is encouraging but
    small, and organoid or humanized models require further validation against
    long-term clinical outcomes.
  evidence:
  - reference: PMID:37550047
    reference_title: "[Research prospect of preclinical model construction and precision therapy in ameloblastoma]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In fact, benign tumor cells generally showed a finite proliferative capacity in two-dimensional culture, and most likely, they could exhibit altered cellular phenotype after immortalization. Moreover, this benign tumor presented low chances of subcutaneous engraftment in nude mice."
    explanation: The review directly states major fidelity and engraftment limitations of current models.
- discussion_id: ameloblastoma_targeted_therapy_durability
  prompt: Which patients obtain durable oncologic control from molecularly matched therapy, and when can surgical extent safely be reduced?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Molecularly Matched Targeted Therapy
  - pathophysiology#Somatic RTK-RAS-MAPK Driver Alterations
  rationale: >-
    Prospective evidence comprises a small observational cohort. Larger studies
    with standardized response, recurrence, resistance, and long-term surgical
    outcome measures are needed before targeted therapy can be treated as
    routine first-line management.
  evidence:
  - reference: PMID:42286159
    reference_title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This prospective observational study included comprehensive molecular profiling of 14 patients with ameloblastoma."
    explanation: The study directly establishes the limited prospective cohort size.

references:
- reference: PMID:11402276
  title: "Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases."
- reference: PMID:24859340
  title: Identification of recurrent SMO and BRAF mutations in ameloblastomas.
- reference: PMID:24963238
  title: "Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012."
- reference: PMID:30614154
  title: "Global incidence and profile of ameloblastoma: A systematic review and meta-analysis."
- reference: PMID:33897185
  title: "Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study."
- reference: PMID:34094934
  title: "Recurrence Rates of Intraosseous Ameloblastoma Cases With Conservative or Aggressive Treatment: A Systematic Review and Meta-Analysis."
- reference: PMID:35689405
  title: New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
- reference: PMID:35822408
  title: "Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review."
- reference: PMID:36428683
  title: "BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis."
- reference: PMID:36582941
  title: RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
- reference: PMID:37550047
  title: "[Research prospect of preclinical model construction and precision therapy in ameloblastoma]."
- reference: PMID:38927880
  title: "Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review."
- reference: PMID:39177897
  title: "Factors Associated with Recurrence of Ameloblastoma: A Scoping Review."
- reference: PMID:39274556
  title: "The Effect of Conservative vs. Radical Treatment of Ameloblastoma on Recurrence Rate and Quality of Life: An Umbrella Review."
- reference: PMID:42286159
  title: "Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study."
- reference: clinicaltrials:NCT02367859
  title: A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
📚

References & Deep Research

References

16
PMID:11402276
Ameloblastoma: a clinical, radiographic, and histopathologic analysis of 71 cases.
No top-level findings curated for this source.
PMID:24859340
Identification of recurrent SMO and BRAF mutations in ameloblastomas.
No top-level findings curated for this source.
PMID:24963238
Ameloblastoma: A clinicoradiographic and histopathologic correlation of 11 cases seen in Goa during 2008-2012.
No top-level findings curated for this source.
PMID:30614154
Global incidence and profile of ameloblastoma: A systematic review and meta-analysis.
No top-level findings curated for this source.
PMID:33897185
Comparison of calretinin expression in dentigerous cysts and ameloblastoma: An immunohistochemical study.
No top-level findings curated for this source.
PMID:34094934
Recurrence Rates of Intraosseous Ameloblastoma Cases With Conservative or Aggressive Treatment: A Systematic Review and Meta-Analysis.
No top-level findings curated for this source.
PMID:35689405
New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
No top-level findings curated for this source.
PMID:35822408
Comparison of survival outcomes between ameloblastic carcinoma and metastasizing ameloblastoma: A systematic review.
No top-level findings curated for this source.
PMID:36428683
BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis.
No top-level findings curated for this source.
PMID:36582941
RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model.
No top-level findings curated for this source.
PMID:37550047
[Research prospect of preclinical model construction and precision therapy in ameloblastoma].
No top-level findings curated for this source.
PMID:38927880
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review.
No top-level findings curated for this source.
PMID:39177897
Factors Associated with Recurrence of Ameloblastoma: A Scoping Review.
No top-level findings curated for this source.
PMID:39274556
The Effect of Conservative vs. Radical Treatment of Ameloblastoma on Recurrence Rate and Quality of Life: An Umbrella Review.
No top-level findings curated for this source.
PMID:42286159
Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.
No top-level findings curated for this source.
clinicaltrials:NCT02367859
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 31 citations 2026-06-22T10:24:19.927965

1. Disease Information

Overview and Definition

Ameloblastoma is a benign epithelial odontogenic tumor that constitutes approximately 10% of all tumors arising in the mandible and maxilla (ghai2022ameloblastomaanupdated pages 1-2, malakar2023theroleof pages 1-2). It is characterized as a locally invasive, slow-growing tumor of odontogenic epithelium, mainly arising from enamel tissue that has not undergone differentiation (ghai2022ameloblastomaanupdated pages 1-2). Despite its histologically benign appearance, ameloblastoma exhibits locally aggressive behavior with high recurrence rates and rare metastatic potential, rendering it an "enigmatic tumor" (ghai2022ameloblastomaanupdated pages 1-2, hendra2020globalincidenceand pages 1-2).

Ameloblastoma was first recognized by Cusack in 1827 and designated as "adamantinoma" in 1885 by Louis-Charles Malassez, before being renamed "ameloblastoma" by Ivey and Churchill in 1930 (ghai2022ameloblastomaanupdated pages 1-2).

WHO Classification

The 2017 WHO Classification described four main subtypes: - Ameloblastoma (solid/multicystic) - Unicystic ameloblastoma - Extraosseous/peripheral ameloblastoma - Metastasizing ameloblastoma (ghai2022ameloblastomaanupdated pages 1-2)

The 2022 WHO Classification (5th edition) introduced important updates: - Conventional ameloblastoma (replacing "solid/multicystic" terminology) - Unicystic ameloblastoma (5-22% of cases) - Extraosseous/peripheral ameloblastoma - Adenoid ameloblastoma (newly recognized entity) - Metastasizing ameloblastoma (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2)

Key changes in the 2022 edition include removal of desmoplastic ameloblastoma as a separate subtype (now considered a histological variant) and addition of "essential and desirable diagnostic criteria" for each entity (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2).

Disease Category and Identifiers

Category: Benign epithelial odontogenic tumor

Synonyms: - Adamantinoma (historical term, no longer preferred) - Solid/multicystic ameloblastoma (older terminology for conventional type)

Note on identifiers: While specific OMIM, Orphanet, or MONDO IDs were not explicitly provided in the retrieved literature, ameloblastoma is classified within the broader category of odontogenic tumors in ICD-11 and MeSH terminology systems. The disease information is derived from aggregated disease-level resources including WHO classifications, systematic reviews, and meta-analyses rather than individual patient EHR data (ghai2022ameloblastomaanupdated pages 1-2, vered2022updatefromthe pages 1-2, hendra2020globalincidenceand pages 1-2).

2. Etiology

Disease Causal Factors

Genetic/Molecular Mechanisms: Ameloblastoma pathogenesis is multifactorial and involves molecular alterations in key cellular pathways. The most significant molecular event is somatic mutation of the BRAF proto-oncogene, specifically BRAF V600E (valine to glutamic acid substitution at amino acid position 600), which is found in 70.49% of ameloblastoma cases based on meta-analysis of 833 cases (yusof2022brafv600emutation pages 1-2). This mutation results in constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, leading to uncontrolled cell proliferation (malakar2023theroleof pages 1-2, yusof2022brafv600emutation pages 1-2).

Other molecular mechanisms involve: - MAPK pathway alterations including FGFR2, KRAS, NRAS, HRAS mutations - Hedgehog pathway activation via SMO mutations (SMO-L412F most common), particularly in maxillary tumors - PIK3CA mutations (less common) - Wnt/β-catenin pathway dysregulation (ghai2022ameloblastomaanupdated pages 1-2, yusof2022brafv600emutation pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2, nguyen2022newameloblastomacell pages 1-2)

Tissue/Cellular Origin: Ameloblastoma is thought to arise from remnants of odontogenic epithelium including: - Rests of dental lamina - Developing enamel organ - Epithelial lining of odontogenic (dentigerous) cysts - Basal epithelial cells of the oral mucosa (hendra2020globalincidenceand pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Environmental Factors: The precise etiology remains obscure. Proposed contributing factors include: - Localized trauma - Inflammation - Nutritional imbalances - Vitamin deficiencies - Possible link to HPV (proposed but not definitively established) (ragunathan2022prevalenceandepidemiological pages 1-2, peralta2024effectivenessofcontemporary pages 1-2)

Risk Factors

Genetic Risk Factors: - BRAF V600E mutation: Strongly associated with disease pathogenesis; significant meta-analysis association with patients younger than 54 years and mandibular location (yusof2022brafv600emutation pages 1-2) - FANCA p.S858R germline mutation: Reported in one metastasizing case, suggesting potential susceptibility role, though interpretation requires further validation (hurnik2023metastasisingameloblastomaor pages 1-2)

Demographic Risk Factors: - Age: Peak incidence in third decade of life (mean age 34 years) (hendra2020globalincidenceand pages 1-2) - Sex: Slight male predominance with male:female ratio of approximately 1.14:1 to 1.2:1 (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2) - Geographic variation: Higher prevalence in Africa and Asia compared to Europe and North America (malakar2023theroleof pages 1-2)

Anatomical Risk Factors: - Mandibular location accounts for approximately 80% of cases (malakar2023theroleof pages 1-2, luca2026longtermclinicaloutcome pages 1-2) - Posterior mandible (molar-ramus region) is the most common site (hendra2020globalincidenceand pages 1-2)

Protective Factors

No specific genetic or environmental protective factors have been identified in the literature reviewed. The sporadic, non-inherited nature of ameloblastoma (driven by somatic mutations) means traditional protective factor analysis is not applicable.

Gene-Environment Interactions

Gene-environment interactions have not been systematically characterized for ameloblastoma. The disease appears to be primarily driven by somatic genetic events (BRAF, RAS, SMO mutations) rather than heritable susceptibility modified by environmental exposures. However, the proposed role of trauma, inflammation, or viral infection in disease initiation suggests potential gene-environment interplay that requires further investigation.

3. Phenotypes

Clinical Phenotypes

Primary Symptoms and Signs:

HP:0030329 - Jaw swelling (most characteristic) - Painless, slowly progressive swelling of the jaw (mandible or maxilla) - Expansion of both buccal and lingual cortical plates - Frequency: Present in nearly all cases at time of diagnosis - Age of onset: Variable, most commonly in third decade - Severity: Progressive, can become massive - Quality of life impact: Significant cosmetic and functional impairment (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

HP:0000303 - Facial asymmetry - Noticeable facial deformity due to unilateral jaw expansion - Frequency: Common in established disease - Progression: Increases with tumor growth - Quality of life impact: Severe psychological distress, social stigma (malakar2023theroleof pages 1-2, gasparro2024theeffectof pages 1-2)

HP:0030751 - Tooth displacement - Displacement and mobility of teeth within affected jaw region - Frequency: Common - Severity: Can lead to tooth loss - Quality of life impact: Impaired mastication, speech difficulties (gasparro2024theeffectof pages 1-2)

HP:0000238 - Paresthesia (when involving nerve) - Numbness or altered sensation, particularly when inferior alveolar nerve is affected - Frequency: Less common, occurs in advanced disease - Severity: Variable - Quality of life impact: Functional impairment, discomfort (peralta2024effectivenessofcontemporary pages 1-2)

HP:0012531 - Pain - Initially painless; pain develops as tumor enlarges and invades surrounding structures - Frequency: Variable, more common in advanced cases - Severity: Mild to moderate in most cases - Quality of life impact: Reduced quality of life (gasparro2024theeffectof pages 1-2)

Laboratory/Radiographic Abnormalities:

Radiographic findings (essential for diagnosis): - Unilocular or multilocular radiolucency - Classic "soap-bubble" or "honeycomb" appearance (multilocular pattern) - Well-defined radiolucent area encircling crown of unerupted tooth (mimicking dentigerous cyst) - Cortical bone destruction with preservation of some trabeculae (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Histopathological Phenotypes

HP:0030077 - Follicular pattern (most common) - Islands of odontogenic epithelium with peripheral palisading and reverse polarization - Central stellate reticulum-like tissue - Frequency: Most common histological pattern globally (hendra2020globalincidenceand pages 1-2)

HP:0030078 - Plexiform pattern (second most common) - Anastomosing cords and sheets of odontogenic epithelium - Frequency: Very common (hendra2020globalincidenceand pages 1-2)

Additional histological variants include acanthomatous, granular cell, basal cell, keratopapillary, and desmoplastic patterns (ghai2022ameloblastomaanupdated pages 1-2).

Quality of Life Impact

Overall Disease Burden: Ameloblastoma significantly impacts multiple domains of quality of life: - Physical function: Impaired mastication, speech, and swallowing in advanced cases - Psychological well-being: Severe distress due to facial deformity, anxiety about recurrence - Social function: Stigmatization, social withdrawal - Aesthetic concerns: Major cosmetic defects requiring extensive reconstruction (malakar2023theroleof pages 1-2, gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

Treatment-related QOL impacts: - Radical surgical resection causes significant morbidity including permanent disfigurement, functional impairment, and psychological distress - Conservative treatment offers better immediate QOL but carries higher recurrence risk requiring repeat surgeries - Long-term rehabilitation including dental implants and prosthetics can restore function and aesthetics but requires extended treatment duration (gasparro2024theeffectof pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

Domain Characteristic Key details / values Evidence citation
WHO / disease category Core disease definition Benign epithelial odontogenic tumor of jaw origin; locally aggressive, slow-growing, recurrent, and rarely metastasizing (ghai2022ameloblastomaanupdated pages 1-2, gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)
WHO classification 2017 WHO types Ameloblastoma; unicystic ameloblastoma; extraosseous/peripheral ameloblastoma; metastasizing ameloblastoma (ghai2022ameloblastomaanupdated pages 1-2)
WHO classification 2022 WHO types Conventional ameloblastoma; unicystic ameloblastoma; extraosseous/peripheral ameloblastoma; adenoid ameloblastoma; metastasizing ameloblastoma (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Conventional ameloblastoma Most common type; previously called solid/multicystic; usually mandibular; histologic patterns include follicular, plexiform, acanthomatous, and desmoplastic (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Unicystic ameloblastoma Approx. 5%–22% of all ameloblastomas; younger patients; luminal, intraluminal, and mural variants discussed in modern classification/treatment planning (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Peripheral / extraosseous ameloblastoma Rare soft-tissue variant overlying jaws; generally less aggressive than intraosseous forms (gasparro2024theeffectof pages 1-2)
WHO classification Metastasizing ameloblastoma Rare; classified as benign despite metastatic potential because histology resembles benign ameloblastoma (ghai2022ameloblastomaanupdated pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)
WHO classification Adenoid ameloblastoma Newly recognized benign epithelial odontogenic tumor in WHO 2022 classification (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2)
Epidemiology Global incidence Pooled incidence rate 0.92 per million person-years (95% CI 0.57–1.49) (hendra2020globalincidenceand pages 1-2)
Epidemiology Alternative incidence statement in review literature Global incidence summarized as about 0.92 per 1,000,000 people/year (raemy2024antimapktargetedtherapy pages 1-2)
Epidemiology Age distribution Mean age 34 years; peak incidence in third decade of life (hendra2020globalincidenceand pages 1-2)
Epidemiology Sex distribution Slight male predominance: 53% male overall; male:female ratio about 1.14:1 in umbrella review (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2)
Epidemiology Anatomic distribution Mandible is preferred site; about 80% mandibular in several reviews/case literature (malakar2023theroleof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Epidemiology Site-specific pattern Maxillary tumors are less common; mandible:maxilla ratio reported as 1.96:1 for metastasizing ameloblastoma (hurnik2023metastasisingameloblastomaor pages 1-2)
Clinical phenotype Common presentation Painless jaw swelling/expansion, facial asymmetry, tooth displacement or mobility, pain/paresthesia in larger lesions (yusof2022brafv600emutation pages 1-2, gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Imaging / phenotype Typical radiology Unilocular or multilocular radiolucency; classic “soap-bubble” or “honeycomb” appearance; may mimic dentigerous cyst (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Histopathology Common patterns Follicular and plexiform are the most frequent histopathologic patterns globally (hendra2020globalincidenceand pages 1-2)
Histopathology Additional variants Acanthomatous, granular cell, basal cell, keratopapillary, and desmoplastic patterns/variants described (ghai2022ameloblastomaanupdated pages 1-2)
Molecular genetics Major pathway theme Ameloblastoma is largely driven by MAPK pathway alterations; Hedgehog pathway also important in a subset (yusof2022brafv600emutation pages 1-2, raemy2024antimapktargetedtherapy pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Molecular genetics BRAF V600E pooled prevalence 70.49% pooled prevalence across 833 cases in meta-analysis (yusof2022brafv600emutation pages 1-2)
Molecular genetics BRAF V600E frequency range in reviews Often summarized as 40%–80% or ~66% depending on cohort/review (malakar2023theroleof pages 1-2, ebeling2023brafinhibitorsin pages 1-2)
Molecular genetics BRAF clinicopathologic associations Significant association with patients younger than 54 years and mandibular location; not significant for sex, histologic variants, or recurrence in one meta-analysis (yusof2022brafv600emutation pages 1-2)
Molecular genetics Other MAPK-pathway genes FGFR2, KRAS, NRAS, HRAS and less commonly PIK3CA identified as drivers in cell-line/genomic studies (nguyen2022newameloblastomacell pages 1-2)
Molecular genetics Hedgehog-pathway genes SMO activating mutations, especially SMO-L412F and less commonly SMO-W535L; more typical of maxillary tumors (yusof2022brafv600emutation pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Molecular genetics Wnt-related findings Upregulation of migration-related Wnt pathway genes described in a metastasizing/amplified aggressive case (hurnik2023metastasisingameloblastomaor pages 1-2)
Molecular profiling Bioinformatic transcriptomic findings 611 differentially expressed genes; glycosaminoglycan signaling upregulated, GABA signaling downregulated; FOS highlighted as hub/target candidate (chujan2024identificationofmolecular pages 1-2)
Pathobiology Origin / tissue of origin Thought to arise from residual odontogenic epithelium including dental lamina rests, enamel organ, odontogenic cyst lining, or basal oral mucosal cells (hendra2020globalincidenceand pages 1-2, luca2026longtermclinicaloutcome pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Treatment outcomes Radical vs conservative treatment Meta-analytic umbrella review found recurrence about three-times more likely with conservative treatment than radical treatment (gasparro2024theeffectof pages 1-2)
Treatment outcomes Overall recurrence after surgery Review of targeted-therapy paper summarizes recurrence varying from 11% after radical surgery to 65% after conservative treatment (raemy2024antimapktargetedtherapy pages 1-2)
Treatment outcomes Conservative treatment tradeoff Better postoperative quality of life, esthetic, and functional outcomes in smaller lesions/younger patients, but higher recurrence risk and need for closer follow-up (gasparro2024theeffectof pages 1-2)
Precision therapy BRAF/MEK targeted therapy evidence Systematic review of 23 patients: nearly all had positive response; 4 achieved complete radiologic remission; toxicities mostly mild-to-moderate (raemy2024antimapktargetedtherapy pages 1-2)
Precision therapy Published BRAF inhibitor case literature Review of 9 reported patients treated with dabrafenib/vemurafenib ± trametinib showed responses from tumor reduction to complete response; evidence still limited to case reports (ebeling2023brafinhibitorsin pages 1-2)
Quality of life Surgical morbidity burden Radical surgery can cause major cosmetic, functional, and psychosocial morbidity; this drives interest in targeted neoadjuvant and organ-preserving approaches (malakar2023theroleof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2, peralta2024effectivenessofcontemporary pages 1-2)

Table: This table compiles the main disease-characteristic domains for ameloblastoma, including WHO classification, epidemiology, molecular genetics, pathology, and recurrence/treatment outcomes. It is useful as a compact evidence map for populating a disease knowledge base with quantitative values and current classification terminology.

Primary Pathogenic Variants:

BRAF Gene (HGNC:1097): - BRAF V600E (p.Val600Glu): Most common pathogenic variant - Variant classification: Pathogenic (somatic) - Variant type: Missense mutation - Frequency: 70.49% pooled prevalence across 833 cases (meta-analysis); ranges from 40-80% in various cohorts - Origin: Somatic mutation - Functional consequence: Constitutive activation of BRAF kinase leading to sustained MAPK pathway signaling - Clinical correlation: Significantly associated with mandibular location and patients <54 years old (yusof2022brafv600emutation pages 1-2)

RAS Gene Family: - KRAS (HGNC:6407): KRAS mutations including G12V and G12R - Variant type: Missense mutations at codon 12 - Origin: Somatic - Functional consequence: Constitutive RAS-GTP activation - Occurrence: Less common than BRAF; variable frequency (nguyen2022newameloblastomacell pages 1-2)

  • NRAS (HGNC:7989), HRAS (HGNC:5173): Activating mutations
  • Origin: Somatic
  • Functional consequence: MAPK pathway activation (nguyen2022newameloblastomacell pages 1-2)

FGFR2 (HGNC:3689): - Activating mutations in fibroblast growth factor receptor 2 - Variant type: Various activating mutations - Origin: Somatic - Functional consequence: Constitutive RTK signaling upstream of MAPK pathway (nguyen2022newameloblastomacell pages 1-2)

SMO Gene (HGNC:11119): - SMO-L412F: Most common Hedgehog pathway mutation - SMO-W535L: Less common variant - Variant classification: Pathogenic (somatic) - Variant type: Missense mutations - Frequency: More common in maxillary ameloblastomas - Origin: Somatic - Functional consequence: Constitutive activation of Hedgehog signaling pathway (yusof2022brafv600emutation pages 1-2, nguyen2022newameloblastomacell pages 1-2)

PIK3CA (HGNC:8975): - Activating mutations (less common) - Origin: Somatic - Functional consequence: Enhanced PI3K-AKT signaling (nguyen2022newameloblastomacell pages 1-2)

FANCA (HGNC:3582): - FANCA p.S858R: Germline heterozygous mutation reported in one metastasizing case - Variant classification: Variant of uncertain significance in ameloblastoma context - Origin: Germline - Interpretation: Potential susceptibility factor, requires further validation (hurnik2023metastasisingameloblastomaor pages 1-2)

Allele Frequencies

Allele frequencies in general population databases (gnomAD) for these variants: - BRAF V600E: Rare in general population; highly enriched in ameloblastoma - RAS mutations: Rare in germline; somatic occurrence varies - SMO mutations: Tumor-specific; not found in general population

Note: Specific population allele frequencies were not detailed in the reviewed literature but these are recognized as somatic, tumor-specific mutations rather than germline polymorphisms.

Modifier Genes

FOS (HGNC:3796): - Identified as hub gene in protein-protein interaction network analysis - Role: Transcription factor involved in cell proliferation and migration - Proposed as potential therapeutic target (chujan2024identificationofmolecular pages 1-2)

Wnt Pathway Members: - Upregulation of cell migration-related Wnt pathway genes observed in metastasizing ameloblastoma - Includes genes involved in epithelial-mesenchymal transition (hurnik2023metastasisingameloblastomaor pages 1-2)

Epigenetic Information

Limited epigenetic data are available in the retrieved literature. No specific DNA methylation patterns, histone modifications, or chromatin changes have been systematically characterized for ameloblastoma in the sources reviewed.

Chromosomal Abnormalities

No large-scale chromosomal abnormalities (aneuploidy, translocations, inversions) are described as characteristic features of ameloblastoma in the reviewed literature. The disease is primarily driven by single nucleotide variants in oncogenes rather than chromosomal rearrangements.

5. Environmental Information

Environmental Factors

No specific environmental toxins, radiation exposure, pollution, or occupational hazards have been definitively linked to ameloblastoma development in the reviewed literature.

Lifestyle Factors

No specific lifestyle factors (smoking, diet, exercise, alcohol consumption) have been established as risk factors for ameloblastoma.

Infectious Agents

Human Papillomavirus (HPV): - A possible link to HPV has been proposed but not definitively established - Evidence level: Speculative; requires further validation (peralta2024effectivenessofcontemporary pages 1-2)

No other infectious agents (bacteria, fungi, parasites) have been implicated in ameloblastoma pathogenesis.

6. Mechanism / Pathophysiology

Molecular Pathways

MAPK (Mitogen-Activated Protein Kinase) Pathway: The MAPK pathway is the most frequently altered pathway in ameloblastoma, particularly in mandibular tumors:

Pathway components: 1. Receptor Tyrosine Kinases (RTKs): FGFR2 activating mutations lead to ligand-independent receptor activation 2. RAS proteins (KRAS, NRAS, HRAS): Mutations lock RAS in active GTP-bound state 3. RAF kinases: BRAF V600E mutation causes constitutive kinase activation 4. MEK → ERK cascade: Phosphorylation cascade activated by mutant BRAF 5. Transcription factors (ELK-1, c-Fos, c-Jun): Nuclear translocation of ERK activates proliferation and anti-apoptotic gene programs (malakar2023theroleof pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Functional consequence: - Uncoupling of growth signal from external ligand requirement - Evasion of senescence and apoptosis - Enhanced cell proliferation - Tissue invasion and potential metastasis - Immune evasion (ebeling2023brafinhibitorsin pages 1-2)

Hedgehog Signaling Pathway: The Hedgehog pathway is preferentially altered in maxillary ameloblastomas:

Pathway components: 1. Hedgehog ligand binds to PTCH1 (Patched 1) 2. PTCH1 inhibition is relieved, activating SMO (Smoothened) 3. SMO-L412F and SMO-W535L mutations cause constitutive SMO activation independent of ligand 4. GLI transcription factors are activated 5. Target genes involved in cell differentiation and proliferation are induced (yusof2022brafv600emutation pages 1-2, nguyen2022newameloblastomacell pages 1-2)

PI3K-AKT Pathway: - PIK3CA mutations (less common) enhance PI3K-AKT signaling - Promotes cell survival and growth (nguyen2022newameloblastomacell pages 1-2)

Wnt/β-Catenin Pathway: - Dysregulation observed, particularly in aggressive/metastasizing cases - Upregulation of migration-related genes - Involvement in epithelial-mesenchymal transition (EMT) (hurnik2023metastasisingameloblastomaor pages 1-2)

GABA and Glycosaminoglycan Signaling: - Bioinformatic analysis identified GABA (γ-aminobutyric acid) signaling as significantly downregulated - Glycosaminoglycan signaling significantly upregulated - Relevance to disease pathogenesis requires further investigation (chujan2024identificationofmolecular pages 1-2)

Cellular Processes

Cell Proliferation: - Constitutive MAPK and Hedgehog signaling drive uncontrolled odontogenic epithelial cell proliferation - Loss of normal growth control mechanisms (malakar2023theroleof pages 1-2, yusof2022brafv600emutation pages 1-2)

Apoptosis Evasion: - MAPK pathway activation promotes anti-apoptotic gene expression - Tumor cells evade programmed cell death (ebeling2023brafinhibitorsin pages 1-2)

Cell Migration and Invasion: - Upregulation of Wnt pathway genes and EMT-related factors in metastasizing tumors - FOS protein (AP-1 transcription factor) identified as hub gene regulating cell migration (chujan2024identificationofmolecular pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)

Protein Dysfunction

BRAF Protein: - Mutant BRAF-V600E exhibits constitutive serine/threonine kinase activity - Loss of regulatory control normally provided by upstream signals - Continuous phosphorylation of MEK (ebeling2023brafinhibitorsin pages 1-2)

RAS Proteins: - Mutant RAS (KRAS, NRAS) locked in active GTP-bound conformation - Failure to hydrolyze GTP to GDP leads to sustained signaling (nguyen2022newameloblastomacell pages 1-2)

SMO Protein: - Mutant SMO (L412F, W535L) exhibits ligand-independent activation - Constitutive signal transduction to GLI transcription factors (nguyen2022newameloblastomacell pages 1-2)

Tissue Damage Mechanisms

Bone Destruction: - Locally invasive tumor infiltrates through medullary spaces of jawbone - Resorption of cortical bone - Destruction of normal bone architecture creating multilocular radiolucencies (ghai2022ameloblastomaanupdated pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Soft Tissue Infiltration: - Tumor can perforate cortical plates and invade adjacent soft tissues - Infiltration beyond radiographic margins (2-8 mm) contributes to high recurrence rates (raemy2024antimapktargetedtherapy pages 1-2)

Molecular Profiling

Transcriptomics: - 611 differentially expressed genes identified in ameloblastoma vs. normal oral tissue - Glycosaminoglycan signaling pathway genes upregulated - GABA signaling pathway genes downregulated - FOS identified as hub gene in protein-protein interaction network (chujan2024identificationofmolecular pages 1-2)

Proteomics: - Limited proteomic data in reviewed literature; FOS protein highlighted as potential therapeutic target

Genomic Features: - Single nucleotide variants in oncogenes (BRAF, RAS, SMO) are characteristic - No recurrent chromosomal rearrangements or copy number alterations systematically described

Suggested Ontology Terms

Gene Ontology (GO) Biological Processes: - GO:0000165 - MAPK cascade - GO:0007224 - Smoothened signaling pathway - GO:0008283 - cell proliferation - GO:0030335 - positive regulation of cell migration - GO:0043066 - negative regulation of apoptotic process

Gene Ontology (GO) Cellular Components: - GO:0005886 - plasma membrane (RTKs, SMO) - GO:0005794 - Golgi apparatus - GO:0005634 - nucleus (transcription factors)

Cell Ontology (CL) Terms: - CL:0000066 - epithelial cell (odontogenic epithelium) - CL:0000075 - columnar/cuboidal epithelial cell (ameloblast-lineage)

7. Anatomical Structures Affected

Organ Level

Primary Organs: - UBERON:0001684 - Mandible: Primary site in approximately 80% of cases - UBERON:0003661 - Maxilla: Affected in approximately 20% of cases - Site distribution: Posterior mandible (molar-ramus region) most common (malakar2023theroleof pages 1-2, hendra2020globalincidenceand pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Secondary Involvement: - UBERON:0001723 - Tongue: Soft tissue infiltration - UBERON:0035920 - Oral mucosa: Peripheral ameloblastoma - UBERON:0001697 - Teeth: Displacement, root resorption - UBERON:0000203 - Orbit: Invasion in advanced maxillary cases - UBERON:0003129 - Skull: Potential invasion in extensive cases (nguyen2022newameloblastomacell pages 1-2)

Body Systems: - Stomatognathic system (primary) - Respiratory system (rare maxillary sinus involvement) - Nervous system (inferior alveolar nerve compression/invasion)

Tissue and Cell Level

Tissue Types: - UBERON:0000483 - Epithelial tissue: Odontogenic epithelium (tumor origin) - UBERON:0002481 - Bone tissue: Jawbone destruction and remodeling - UBERON:0003104 - Mesenchyme: Stromal component (mature fibrous stroma)

Specific Cell Populations: - CL:0000066 - Epithelial cell: Odontogenic epithelial cells (tumor cells) - CL:0000075 - Columnar/cuboidal epithelial cell: Ameloblast-lineage cells - CL:0000057 - Fibroblast: Stromal fibroblasts - CL:0000092 - Osteoclast: Bone resorption - CL:0000062 - Osteoblast: Reactive bone formation (nguyen2022newameloblastomacell pages 1-2)

Subcellular Level

Cellular Compartments (GO Cellular Component): - GO:0005886 - Plasma membrane: Location of mutant SMO, RTKs - GO:0005737 - Cytoplasm: RAF-MEK-ERK cascade components - GO:0005634 - Nucleus: Transcription factors (GLI, FOS, ERK) - GO:0005794 - Golgi apparatus: Protein processing

Localization

Anatomical Sites (UBERON): - UBERON:0001684 - Mandible: 80% of cases - Most common: Posterior region (molar and angle) - UBERON:0003661 - Maxilla: 20% of cases - Less common, more challenging surgical management

Lateralization: - Predominantly unilateral presentation - Can occur on either left or right side - Bilateral involvement is extremely rare

8. Temporal Development

Onset

Typical Age of Onset: - Mean age at diagnosis: 34 years - Peak incidence: Third decade of life (20-40 years) - Range: Can occur from childhood to elderly; rare in children <10 years (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2)

Age variation by geography: - Europe and North America: Diagnosis at older age - Africa and South America: Diagnosis at younger age (hendra2020globalincidenceand pages 1-2)

Onset Pattern: - Insidious onset: Slow, painless growth over months to years - Often diagnosed incidentally on routine dental radiography or when swelling becomes noticeable

Progression

Disease Stages: - Early stage: Small, asymptomatic radiolucency; may be discovered incidentally - Intermediate stage: Visible swelling, cortical expansion, tooth displacement - Advanced stage: Massive tumor, facial deformity, cortical perforation, soft tissue invasion - End-stage/metastatic: Rare; metastases most commonly to lungs (75-88% of metastatic cases) (hurnik2023metastasisingameloblastomaor pages 1-2)

Progression Rate: - Slow progression: Growth over months to years - Locally aggressive: Infiltrative growth pattern with destruction of surrounding bone - Variable: Some tumors remain stable, others grow more rapidly

Disease Course Pattern: - Progressive without treatment - High recurrence rate after conservative treatment (up to 65%) - Lower recurrence after radical surgery (approximately 11%) (raemy2024antimapktargetedtherapy pages 1-2)

Disease Duration: - Chronic: Lifelong risk of recurrence even after treatment - Long-term follow-up required (decades) - Median survival after metastasis diagnosis: 17.6 years for metastasizing ameloblastoma (hurnik2023metastasisingameloblastomaor pages 1-2)

Patterns

Recurrence: - Treatment-induced remission: Surgical excision can achieve complete remission - Recurrence risk: Varies by treatment approach - Conservative treatment: High recurrence (up to 65%) - Radical resection: Lower recurrence (approximately 11%) - Recurrence can occur years to decades after initial treatment (gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

Critical Periods: - Childhood to young adulthood: Peak incidence window - Post-treatment surveillance: Lifelong monitoring required to detect recurrence - First 5 years post-surgery: Highest recurrence risk, but late recurrences (>10 years) also reported

9. Inheritance and Population

Epidemiology

Incidence: - Global pooled incidence rate: 0.92 per million person-years (95% CI: 0.57-1.49) - Significant heterogeneity between geographic regions (hendra2020globalincidenceand pages 1-2)

Prevalence: - Ameloblastoma accounts for approximately 1% of all oral tumors and cysts - Constitutes 13-58% of all odontogenic tumors - Second most common odontogenic tumor after odontoma (malakar2023theroleof pages 1-2, ragunathan2022prevalenceandepidemiological pages 1-2, hendra2020globalincidenceand pages 1-2)

Geographic Distribution: - Higher incidence in Africa and Asia - Lower incidence in Europe and North America - Studies covered Europe, Africa, and Australia; data from Americas and Asia less comprehensive (hendra2020globalincidenceand pages 1-2)

Inheritance Patterns

Genetic Etiology: - Sporadic disease: Ameloblastoma is not an inherited condition - Somatic mutations: Disease is caused by acquired (somatic) mutations in BRAF, RAS, SMO, and other oncogenes - Inheritance pattern: Not applicable (N/A) - not a hereditary disease - Penetrance: N/A - Expressivity: N/A - Genetic anticipation: N/A - Germline mosaicism: N/A - Founder effects: N/A - mutations are sporadic - Consanguinity role: N/A - Carrier frequency: N/A

Note: One case report identified a germline FANCA mutation in a metastasizing ameloblastoma patient, suggesting potential susceptibility in rare cases, but this requires further validation (hurnik2023metastasisingameloblastomaor pages 1-2).

Population Demographics

Sex Distribution: - Slight male predominance - Male:female ratio: approximately 1.14:1 to 1.2:1 - Some studies report equal distribution or slight female predominance depending on cohort (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2)

Age Distribution: - Mean age: 34 years - Peak incidence: Third decade (20-40 years) - Range: Can affect any age; rare in children <10 years - Geographic variation: Older age at diagnosis in Europe/North America vs. Africa/South America (hendra2020globalincidenceand pages 1-2)

Affected Populations: - Higher prevalence reported in African populations - China and Africa have higher burden (up to 10% of jaw cysts and tumors) - No specific ethnic or demographic group shows genetic susceptibility (disease is sporadic) (malakar2023theroleof pages 1-2)

Anatomical Distribution: - Mandible: Approximately 80% of cases - Maxilla: Approximately 20% of cases - Posterior mandible (molar-ramus region): Most common site - Mandible:maxilla ratio: 1.96:1 (malakar2023theroleof pages 1-2, luca2026longtermclinicaloutcome pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)

10. Diagnostics

Clinical Tests

Imaging Studies:

Computed Tomography (CT): - Essential for diagnosis and surgical planning - Demonstrates extent of bone destruction, cortical perforation, and soft tissue invasion - Visualizes multilocular ("soap-bubble" or "honeycomb") or unilocular radiolucent lesions - High-resolution assessment of tumor margins (ghai2022ameloblastomaanupdated pages 1-2, gasparro2024theeffectof pages 1-2)

Cone-Beam Computed Tomography (CBCT): - 3D imaging with lower radiation dose than conventional CT - High modality for detailed radiographic assessment - Useful for distinguishing ameloblastoma from other radiolucent lesions - Aids in treatment planning (gasparro2024theeffectof pages 1-2)

Orthopantomography (Panoramic radiography): - Initial screening tool - Demonstrates radiolucent lesions, tooth displacement, cortical expansion - Not pathognomonic; requires histological confirmation (peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

MRI: - Useful for assessing soft tissue involvement - Superior for evaluating neural and vascular structures

Radiographic Features: - Unilocular or multilocular radiolucency - "Soap-bubble" appearance (multilocular) - "Honeycomb" appearance - Well-defined margins with cortical sclerosis - May mimic dentigerous cyst when encircling unerupted tooth (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Biopsy and Histopathology:

Incisional Biopsy: - Essential for definitive diagnosis - Tissue obtained for histopathological examination - Differentiates ameloblastoma from: - Ossifying fibroma - Osteomyelitis - Giant cell tumor - Cystic fibrous dysplasia - Odontogenic keratocyst - Central mucoepidermoid carcinoma - Myeloma - Sarcoma (ghai2022ameloblastomaanupdated pages 1-2)

Histopathological Features: - Follicular pattern: Islands of odontogenic epithelium, peripheral palisading, reverse polarization, central stellate reticulum - Plexiform pattern: Anastomosing cords and sheets of epithelium - Other variants: Acanthomatous, granular cell, basal cell, desmoplastic - Essential features: Odontogenic epithelium with ameloblast-like differentiation (ghai2022ameloblastomaanupdated pages 1-2, hendra2020globalincidenceand pages 1-2)

Immunohistochemistry: - May be used to support diagnosis and distinguish from other entities - Specific markers not detailed in reviewed literature but likely include epithelial markers (cytokeratins)

Genetic Testing

BRAF Mutation Testing: - Method: DNA sequencing (Sanger sequencing, targeted NGS panels, TaqMan allele-specific qPCR) - Target: BRAF V600E mutation detection - Clinical utility: - Confirms diagnosis - Identifies patients eligible for BRAF inhibitor therapy (vemurafenib, dabrafenib) - Prognostic information (associated with mandibular location, younger age) (yusof2022brafv600emutation pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Next-Generation Sequencing (NGS) Panels: - Targets: BRAF, KRAS, NRAS, HRAS, FGFR2, SMO, PIK3CA - Clinical utility: - Comprehensive mutation profiling - Identification of targetable mutations - Research and clinical trial eligibility (nguyen2022newameloblastomacell pages 1-2)

Whole Exome Sequencing (WES): - Research tool for comprehensive genomic characterization - Clinical utility: Limited in routine practice

Single Gene Testing: - BRAF gene sequencing for V600E mutation - SMO gene sequencing for L412F and W535L mutations

Note: Genetic testing is increasingly used for treatment stratification, particularly to identify patients eligible for targeted therapies (BRAF inhibitors, MEK inhibitors, SMO inhibitors).

Biomarkers

Molecular Biomarkers: - BRAF V600E: Diagnostic and predictive biomarker for response to BRAF/MEK inhibitors - FOS protein: Proposed therapeutic target based on bioinformatic analysis (chujan2024identificationofmolecular pages 1-2)

No circulating biomarkers (serum or urine) have been established for ameloblastoma diagnosis or monitoring.

Clinical Criteria and Differential Diagnosis

Standardized Diagnostic Criteria: - WHO classification criteria (2022 edition) - Essential diagnostic features: - Clinical: Jaw swelling, radiographic radiolucency - Radiographic: Unilocular/multilocular radiolucent lesion - Histopathologic: Odontogenic epithelium with ameloblast-like features - Desirable features: Specific histological patterns, molecular mutations (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2)

Differential Diagnosis: - Odontogenic keratocyst: Similar radiographic appearance; histology differs - Dentigerous cyst: Unicystic ameloblastoma may mimic; histology required - Adenomatoid odontogenic tumor: Different molecular profile (KRAS mutations more common) - Central mucoepidermoid carcinoma: MAML2 gene rearrangements; more aggressive - Ossifying fibroma - Giant cell tumor - Osteomyelitis - Sarcoma (ghai2022ameloblastomaanupdated pages 1-2)

Screening

Population Screening: - No population-based screening programs exist - Not applicable for sporadic disease

Surveillance After Treatment: - Lifelong clinical and radiographic follow-up required - Frequency: Initially every 6-12 months, then annually - Imaging: Panoramic radiography or CBCT to detect recurrence - Earlier detection of recurrence allows for less morbid intervention (gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

11. Outcome/Prognosis

Survival and Mortality

Overall Survival: - Conventional ameloblastoma: Excellent long-term survival with adequate treatment - Metastasizing ameloblastoma: Median survival 17.6 years from diagnosis of metastasis - Ameloblastic carcinoma: Poorer prognosis; specific survival data not detailed in reviewed literature (hurnik2023metastasisingameloblastomaor pages 1-2)

Mortality: - Disease-specific mortality: Low for conventional ameloblastoma - Deaths primarily due to complications of extensive local disease or rare metastases - No specific mortality rates provided in reviewed literature

Life Expectancy: - Generally normal life expectancy with appropriate treatment - Reduced in metastasizing ameloblastoma and ameloblastic carcinoma

Morbidity and Function

Disease-Related Morbidity: - Facial deformity and disfigurement - Loss of teeth - Impaired mastication - Speech difficulties - Paresthesia or anesthesia (nerve involvement) - Orbital or skull base invasion (rare, advanced cases) (gasparro2024theeffectof pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Treatment-Related Morbidity: - Radical surgery: - Permanent facial disfigurement - Loss of jaw function - Difficulty with mastication, speech, swallowing - Donor site morbidity (if bone grafts used) - Psychological and social impacts (malakar2023theroleof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

  • Conservative surgery:
  • Lower immediate morbidity
  • Higher recurrence risk requiring repeat surgeries with cumulative morbidity

Quality of Life: - Radical treatment significantly impairs QOL in multiple domains - Conservative treatment offers better immediate QOL but anxiety about recurrence - Successful rehabilitation with implants and prosthetics can restore function and aesthetics - Long-term QOL depends on treatment success, recurrence, and reconstruction quality (gasparro2024theeffectof pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Disease Course and Complications

Recurrence: - Conservative treatment: Up to 65% recurrence rate - Radical resection: Approximately 11% recurrence rate - Recurrence can occur years to decades after initial treatment - Follicular histological subtype may have higher recurrence rate (>60%) (ragunathan2022prevalenceandepidemiological pages 1-2, gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

Complications: - Local recurrence (most common) - Metastasis (1-4% of cases): - Lungs (75-88% of metastatic cases) - Lymph nodes (cervical most common) - Distant sites (bone, liver, brain - rare) (hurnik2023metastasisingameloblastomaor pages 1-2) - Malignant transformation to ameloblastic carcinoma (rare) - Infection (post-surgical) - Pathological fracture (extensive bone destruction)

Recovery Potential: - With treatment: Excellent potential for local disease control with radical surgery - Functional recovery: Dependent on extent of resection and quality of reconstruction - Aesthetic recovery: Modern reconstructive techniques (vascularized free flaps, dental implants, CAD/CAM prosthetics) can achieve good outcomes (peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Prognostic Factors

Favorable Prognostic Factors: - Smaller tumor size - Unicystic subtype - Younger age (for treatment tolerance) - Mandibular location (easier surgical access than maxilla) - Early detection - Adequate surgical margins (>1-2 cm) (raemy2024antimapktargetedtherapy pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Unfavorable Prognostic Factors: - Large tumor size - Conventional (solid) subtype - Maxillary location - Recurrent disease - Soft tissue invasion - Inadequate surgical margins - Follicular histological pattern (higher recurrence) - Metastasis (ragunathan2022prevalenceandepidemiological pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)

Molecular Prognostic Markers: - BRAF V600E mutation: Not independently prognostic for recurrence in one meta-analysis, but associated with younger age and mandibular location - Further research needed to establish molecular predictors of recurrence and metastasis (yusof2022brafv600emutation pages 1-2)

12. Treatment

Pharmacotherapy

Conventional Chemotherapy: - Not effective as primary treatment - Limited role in ameloblastic carcinoma; uncertain outcomes (malakar2023theroleof pages 1-2)

Radiotherapy: - Not routinely used for conventional ameloblastoma (radioresistant) - May be considered for inoperable or recurrent ameloblastic carcinoma - Uncertain efficacy; controversial (malakar2023theroleof pages 1-2)

Advanced Therapeutics: Targeted Therapies

BRAF Inhibitors:

Vemurafenib (PLX4032): - Mechanism: Selective BRAF-V600E inhibitor - Indication: BRAF-V600E mutant ameloblastoma - Clinical evidence: Case reports show tumor size reduction, some complete responses - Adverse effects: Arthralgia, fatigue, rash, photosensitivity, skin papillomas, hyperkeratosis, squamous cell carcinoma, keratoacanthoma, elevated liver enzymes - Usage: Off-label; approved for melanoma (malakar2023theroleof pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Dabrafenib: - Mechanism: Selective BRAF-V600E inhibitor - Indication: BRAF-V600E mutant ameloblastoma - Clinical evidence: Systematic review of 23 patients showed nearly all had positive response; 4 achieved complete radiological remission - Often used in combination with MEK inhibitor (trametinib) for synergistic effect and reduced resistance - Adverse effects: Generally mild to moderate toxicities - Usage:** Off-label; approved for melanoma (raemy2024antimapktargetedtherapy pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

MEK Inhibitors:

Trametinib: - Mechanism: Selective MEK inhibitor (downstream of BRAF in MAPK pathway) - Indication: Used in combination with dabrafenib for BRAF-mutant ameloblastoma; also active in RAS-mutant tumors - Clinical evidence: Combination therapy shows improved responses and reduced resistance compared to BRAF inhibitor monotherapy - In vitro studies: MEK inhibition in KRAS/NRAS-mutant ameloblastoma cells propels ameloblast differentiation and reduces proliferation (nguyen2022newameloblastomacell pages 1-2) - Usage: Off-label; approved for melanoma in combination with BRAF inhibitors (raemy2024antimapktargetedtherapy pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Hedgehog Pathway Inhibitors:

Vismodegib: - Mechanism: SMO inhibitor - Indication: SMO-mutant ameloblastoma (maxillary tumors) - Clinical evidence: Ameloblastoma cells with SMO-L412F mutation are insensitive to vismodegib - Usage: Not recommended based on preclinical data (nguyen2022newameloblastomacell pages 1-2)

BMS-833923: - Mechanism: Alternative SMO inhibitor - Indication: SMO-mutant ameloblastoma - Clinical evidence: Preclinical studies show significant reduction in Hedgehog signaling and tumor cell viability in SMO-L412F mutant cells - Usage: Investigational; may be effective where vismodegib fails (nguyen2022newameloblastomacell pages 1-2)

Drug Repositioning Candidates:

Tanespimycin (17-AAG): - Mechanism: HSP90 inhibitor; proposed to target FOS protein (hub gene identified in bioinformatic analysis) - Clinical evidence: Molecular docking simulation shows high affinity for FOS; no clinical data - Status: Investigational (chujan2024identificationofmolecular pages 1-2)

Surgical Interventions

Radical Resection: - Procedure: Segmental mandibulectomy or maxillectomy with 1.5-2 cm safety margins; en bloc resection - Indication: Conventional ameloblastoma, unicystic mural type - Outcomes: Lowest recurrence rate (approximately 11%) - Reconstruction: Immediate reconstruction with vascularized bone grafts (fibula free flap most common), titanium plates, dental implants - Morbidity: Significant functional and aesthetic deficits (gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Conservative Resection: - Procedures: Enucleation, curettage, marginal resection - Indication: Smaller lesions, unicystic luminal/intraluminal types, younger patients - Outcomes: Higher recurrence rate (up to 65%) - Benefits: Better postoperative quality of life, preserved function and aesthetics - Risk: Requires closer long-term surveillance (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Decompression: - Procedure: Marsupialization or decompression to reduce tumor size before definitive surgery - Indication: Large tumors in young patients; neoadjuvant approach - Benefits: Preserves more bone, allows further jaw growth in children - Requires: Definitive surgery after tumor shrinkage

Neoadjuvant Targeted Therapy Followed by Surgery: - Approach: BRAF/MEK inhibitors to shrink tumor before conservative resection - Benefits: Organ preservation, reduced surgical morbidity, better cosmetic outcomes - Evidence: Case reports and small series show feasibility; long-term follow-up needed (raemy2024antimapktargetedtherapy pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Prosthetic Rehabilitation

Dental Implants: - Procedure: Osseointegrated implants placed in reconstructed bone (fibula grafts, iliac crest grafts) - Timing: Immediate (at time of reconstruction) or delayed (18 months post-reconstruction) - Outcomes: Immediate implants show better survival rates; restore masticatory function and aesthetics (peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

Prosthetic Devices: - Fixed prostheses: Implant-supported fixed dentures or bridges - Removable prostheses: Overdentures supported by implants - Benefits: Functional and aesthetic restoration, improved quality of life (peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

CAD/CAM and 3D Printing: - Technology: Computer-aided design/manufacturing for surgical guides, custom implants, prosthetics - Benefits: Improved surgical precision, better functional and aesthetic outcomes (peralta2024effectivenessofcontemporary pages 1-2)

Treatment Algorithms

Conventional Ameloblastoma: 1. Biopsy and molecular testing (BRAF status) 2. Radical resection with 1.5-2 cm margins + immediate reconstruction (standard) - OR: Neoadjuvant targeted therapy (if BRAF-mutant) followed by conservative resection (investigational) 3. Prosthetic rehabilitation 4. Lifelong surveillance (gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

Unicystic Ameloblastoma: 1. Conservative treatment (enucleation ± curettage) for luminal/intraluminal types 2. Radical resection for mural type (behaves like conventional) 3. Close surveillance (luca2026longtermclinicaloutcome pages 1-2)

Metastatic/Inoperable Ameloblastoma: 1. Molecular testing (BRAF, RAS, SMO mutations) 2. Targeted therapy: - BRAF-mutant: Dabrafenib + trametinib - RAS-mutant: MEK inhibitor (trametinib) - SMO-mutant: BMS-833923 (investigational) 3. Palliative surgery if feasible (raemy2024antimapktargetedtherapy pages 1-2, ebeling2023brafinhibitorsin pages 1-2, nguyen2022newameloblastomacell pages 1-2)

Treatment Outcomes

BRAF-Targeted Therapy: - Systematic review of 23 patients: Nearly all showed positive response - Complete radiological remission: 4/23 patients - Tumor size reduction: Most patients - Side effects: Mostly mild to moderate - Durability: Long-term follow-up limited (longest 38 months in reviewed case reports) (raemy2024antimapktargetedtherapy pages 1-2, ebeling2023brafinhibitorsin pages 1-2)

Surgical Outcomes: - Radical resection: Low recurrence (<10% with adequate margins), high morbidity - Conservative treatment: High recurrence (up to 65%), better immediate QOL - Reconstruction with fibula free flap: High success rates, good functional and aesthetic outcomes (gasparro2024theeffectof pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2)

MAXO (Medical Action Ontology) Terms

Suggested terms for treatment annotations: - MAXO:0000004 - surgical resection - MAXO:0000127 - chemotherapy (for ameloblastic carcinoma, limited role) - MAXO:0001001 - gene therapy (potential future application) - MAXO:0000882 - targeted molecular therapy - MAXO:0000011 - transplantation (bone graft) - MAXO:0001175 - rehabilitation therapy (prosthetic rehabilitation)

13. Prevention

Prevention Levels

Primary Prevention: Not applicable. Ameloblastoma is a sporadic disease caused by somatic mutations; no known preventable risk factors exist.

Secondary Prevention (Early Detection): - Routine dental examination with periodic panoramic radiography - Early detection of small, asymptomatic lesions allows for less morbid treatment - No formal screening programs exist due to low incidence

Tertiary Prevention (Preventing Complications): - Adequate surgical margins (1.5-2 cm) to prevent recurrence - Lifelong surveillance to detect recurrence early - Close follow-up in first 5-10 years post-treatment (highest recurrence risk) - Patient education about signs of recurrence (gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)

Screening and Early Detection

Population Screening: - Not recommended due to low incidence (0.92 per million person-years) - Not cost-effective

Opportunistic Screening: - Routine dental radiography may detect asymptomatic lesions - Dentists play key role in early detection

Genetic Screening: - Not applicable (disease is not hereditary) - BRAF mutation testing used for treatment stratification, not screening

Risk Stratification: - Not applicable (no high-risk populations identified)

Behavioral and Public Health Interventions

No specific behavioral interventions or public health measures are applicable for a sporadic neoplasm with unclear etiology.

Counseling

Genetic Counseling: - Not required for sporadic ameloblastoma - May be considered if germline susceptibility factors are identified in future research (e.g., FANCA mutation validation)

Patient Counseling: - Education about disease nature, treatment options, and lifelong surveillance needs - Discussion of treatment tradeoffs: radical surgery (low recurrence, high morbidity) vs. conservative approach (higher recurrence, better QOL) - Psychological support for coping with diagnosis, treatment morbidity, and potential disfigurement

14. Other Species / Natural Disease

Comparative Biology and Veterinary Relevance

Canine Acanthomatous Ameloblastoma: - Species: Dogs (Canis lupus familiaris) - NCBI Taxon: 9615 - Natural occurrence: Recognized odontogenic tumor in dogs - Relevance: Used as comparative model for human ameloblastoma - Biological behavior: Locally invasive, similar to human ameloblastoma; assessed with CT and histopathology - Research applications: Comparative pathology studies; potential model for testing therapies (krawczyk2025conditionallyreprogrammedcells pages 1-2)

Note: The reviewed literature provided limited detailed information on naturally occurring ameloblastoma in other species. Canine acanthomatous ameloblastoma is the most relevant veterinary counterpart. Other animal models (mouse, zebrafish) are discussed below.

15. Model Organisms

Cell Line Models

Conditionally Reprogrammed Cells (CRCs): - Technology: Conditional cell reprogramming (CCR) allows primary ameloblastoma cells to acquire stem cell properties and proliferate indefinitely without genetic modification - Advantages: Maintains genomic and histological characteristics of parental tissue; patient-derived; no ethical concerns - Applications: Drug screening, molecular profiling, personalized medicine - Limitations: Relatively new technology; limited availability (krawczyk2025conditionallyreprogrammedcells pages 1-2)

Established Ameloblastoma Cell Lines: - New cell lines: Six new ameloblastoma cell lines generated using conditional reprogramming technology (Nguyen et al., 2022) - Genomic characterization: Lines harbor mutations in FGFR2, KRAS, NRAS, BRAF, PIK3CA, and SMO - Applications: - Oncogene dependency studies: Demonstrated exquisite sensitivity of RAS-mutant cells to MEK inhibition - Drug screening: Identified BMS-833923 as effective SMO inhibitor for SMO-L412F mutant cells - Preclinical testing of targeted therapies (nguyen2022newameloblastomacell pages 1-2)

In Vivo Animal Models

Mouse Xenograft Models: - Approach: Patient-derived xenografts (PDXs) using ameloblastoma cell lines or primary tumor tissue - Applications: - Drug efficacy studies - Tumor biology research - Preclinical testing of BRAF/MEK inhibitors - Limitations: Immunocompromised mice do not recapitulate immune microenvironment (nguyen2022newameloblastomacell pages 1-2, krawczyk2025conditionallyreprogrammedcells pages 1-2)

Zebrafish Models: - Applications: Xenotransplantation studies for rapid drug screening; assessment of tumor cell behavior - Advantages: Rapid development, optical transparency, cost-effective - Limitations: Evolutionary distance from mammals; limited recapitulation of human tumor microenvironment - **Mentioned in context of ameloblastoma research but detailed studies not available in reviewed literature (krawczyk2025conditionallyreprogrammedcells pages 1-2)

Canine Models: - Natural disease: Canine acanthomatous ameloblastoma occurs spontaneously in dogs - Comparative studies: CT and histopathological characterization of biological behavior - Advantages: Naturally occurring tumor; larger size suitable for surgical and imaging studies - Limitations: Genetic and molecular differences from human ameloblastoma; limited availability (krawczyk2025conditionallyreprogrammedcells pages 1-2)

Model Characteristics and Limitations

Phenotype Recapitulation: - Cell lines: Maintain driver mutations; useful for molecular studies and drug screening - Xenografts: Recapitulate tumor growth and invasion; limited immune interactions - Canine models: Natural tumor biology; differences in molecular drivers and disease course - Limitations: No model perfectly recapitulates human ameloblastoma's slow growth, local invasiveness, and rare metastasis

Research Applications: - Molecular mechanism studies (cell signaling, gene expression) - Drug screening and preclinical testing - Biomarker discovery - Development of targeted therapies - Understanding oncogene addiction and resistance mechanisms (nguyen2022newameloblastomacell pages 1-2, krawczyk2025conditionallyreprogrammedcells pages 1-2)

Model Resources

Cell Line Repositories: - New ameloblastoma cell lines available from originating laboratories (Nguyen et al., 2022; contact authors) - Conditional reprogramming technology available through collaborations

Animal Model Databases: - Mouse Genome Informatics (MGI) - International Mouse Strain Resource (IMSR) - Zebrafish Information Network (ZFIN)

Summary Table

Domain Characteristic Key details / values Evidence citation
WHO / disease category Core disease definition Benign epithelial odontogenic tumor of jaw origin; locally aggressive, slow-growing, recurrent, and rarely metastasizing (ghai2022ameloblastomaanupdated pages 1-2, gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)
WHO classification 2017 WHO types Ameloblastoma; unicystic ameloblastoma; extraosseous/peripheral ameloblastoma; metastasizing ameloblastoma (ghai2022ameloblastomaanupdated pages 1-2)
WHO classification 2022 WHO types Conventional ameloblastoma; unicystic ameloblastoma; extraosseous/peripheral ameloblastoma; adenoid ameloblastoma; metastasizing ameloblastoma (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Conventional ameloblastoma Most common type; previously called solid/multicystic; usually mandibular; histologic patterns include follicular, plexiform, acanthomatous, and desmoplastic (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Unicystic ameloblastoma Approx. 5%–22% of all ameloblastomas; younger patients; luminal, intraluminal, and mural variants discussed in modern classification/treatment planning (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
WHO classification Peripheral / extraosseous ameloblastoma Rare soft-tissue variant overlying jaws; generally less aggressive than intraosseous forms (gasparro2024theeffectof pages 1-2)
WHO classification Metastasizing ameloblastoma Rare; classified as benign despite metastatic potential because histology resembles benign ameloblastoma (ghai2022ameloblastomaanupdated pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)
WHO classification Adenoid ameloblastoma Newly recognized benign epithelial odontogenic tumor in WHO 2022 classification (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2)
Epidemiology Global incidence Pooled incidence rate 0.92 per million person-years (95% CI 0.57–1.49) (hendra2020globalincidenceand pages 1-2)
Epidemiology Alternative incidence statement in review literature Global incidence summarized as about 0.92 per 1,000,000 people/year (raemy2024antimapktargetedtherapy pages 1-2)
Epidemiology Age distribution Mean age 34 years; peak incidence in third decade of life (hendra2020globalincidenceand pages 1-2)
Epidemiology Sex distribution Slight male predominance: 53% male overall; male:female ratio about 1.14:1 in umbrella review (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2)
Epidemiology Anatomic distribution Mandible is preferred site; about 80% mandibular in several reviews/case literature (malakar2023theroleof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Epidemiology Site-specific pattern Maxillary tumors are less common; mandible:maxilla ratio reported as 1.96:1 for metastasizing ameloblastoma (hurnik2023metastasisingameloblastomaor pages 1-2)
Clinical phenotype Common presentation Painless jaw swelling/expansion, facial asymmetry, tooth displacement or mobility, pain/paresthesia in larger lesions (yusof2022brafv600emutation pages 1-2, gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Imaging / phenotype Typical radiology Unilocular or multilocular radiolucency; classic “soap-bubble” or “honeycomb” appearance; may mimic dentigerous cyst (gasparro2024theeffectof pages 1-2, luca2026longtermclinicaloutcome pages 1-2)
Histopathology Common patterns Follicular and plexiform are the most frequent histopathologic patterns globally (hendra2020globalincidenceand pages 1-2)
Histopathology Additional variants Acanthomatous, granular cell, basal cell, keratopapillary, and desmoplastic patterns/variants described (ghai2022ameloblastomaanupdated pages 1-2)
Molecular genetics Major pathway theme Ameloblastoma is largely driven by MAPK pathway alterations; Hedgehog pathway also important in a subset (yusof2022brafv600emutation pages 1-2, raemy2024antimapktargetedtherapy pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Molecular genetics BRAF V600E pooled prevalence 70.49% pooled prevalence across 833 cases in meta-analysis (yusof2022brafv600emutation pages 1-2)
Molecular genetics BRAF V600E frequency range in reviews Often summarized as 40%–80% or ~66% depending on cohort/review (malakar2023theroleof pages 1-2, ebeling2023brafinhibitorsin pages 1-2)
Molecular genetics BRAF clinicopathologic associations Significant association with patients younger than 54 years and mandibular location; not significant for sex, histologic variants, or recurrence in one meta-analysis (yusof2022brafv600emutation pages 1-2)
Molecular genetics Other MAPK-pathway genes FGFR2, KRAS, NRAS, HRAS and less commonly PIK3CA identified as drivers in cell-line/genomic studies (nguyen2022newameloblastomacell pages 1-2)
Molecular genetics Hedgehog-pathway genes SMO activating mutations, especially SMO-L412F and less commonly SMO-W535L; more typical of maxillary tumors (yusof2022brafv600emutation pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Molecular genetics Wnt-related findings Upregulation of migration-related Wnt pathway genes described in a metastasizing/amplified aggressive case (hurnik2023metastasisingameloblastomaor pages 1-2)
Molecular profiling Bioinformatic transcriptomic findings 611 differentially expressed genes; glycosaminoglycan signaling upregulated, GABA signaling downregulated; FOS highlighted as hub/target candidate (chujan2024identificationofmolecular pages 1-2)
Pathobiology Origin / tissue of origin Thought to arise from residual odontogenic epithelium including dental lamina rests, enamel organ, odontogenic cyst lining, or basal oral mucosal cells (hendra2020globalincidenceand pages 1-2, luca2026longtermclinicaloutcome pages 1-2, nguyen2022newameloblastomacell pages 1-2)
Treatment outcomes Radical vs conservative treatment Meta-analytic umbrella review found recurrence about three-times more likely with conservative treatment than radical treatment (gasparro2024theeffectof pages 1-2)
Treatment outcomes Overall recurrence after surgery Review of targeted-therapy paper summarizes recurrence varying from 11% after radical surgery to 65% after conservative treatment (raemy2024antimapktargetedtherapy pages 1-2)
Treatment outcomes Conservative treatment tradeoff Better postoperative quality of life, esthetic, and functional outcomes in smaller lesions/younger patients, but higher recurrence risk and need for closer follow-up (gasparro2024theeffectof pages 1-2)
Precision therapy BRAF/MEK targeted therapy evidence Systematic review of 23 patients: nearly all had positive response; 4 achieved complete radiologic remission; toxicities mostly mild-to-moderate (raemy2024antimapktargetedtherapy pages 1-2)
Precision therapy Published BRAF inhibitor case literature Review of 9 reported patients treated with dabrafenib/vemurafenib ± trametinib showed responses from tumor reduction to complete response; evidence still limited to case reports (ebeling2023brafinhibitorsin pages 1-2)
Quality of life Surgical morbidity burden Radical surgery can cause major cosmetic, functional, and psychosocial morbidity; this drives interest in targeted neoadjuvant and organ-preserving approaches (malakar2023theroleof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2, peralta2024effectivenessofcontemporary pages 1-2)

Table: This table compiles the main disease-characteristic domains for ameloblastoma, including WHO classification, epidemiology, molecular genetics, pathology, and recurrence/treatment outcomes. It is useful as a compact evidence map for populating a disease knowledge base with quantitative values and current classification terminology.

Key Ontology Term Suggestions

Disease Ontology: - MONDO:0004666 - ameloblastoma (if available)

Human Phenotype Ontology (HPO): - HP:0030329 - Jaw swelling - HP:0000303 - Facial asymmetry - HP:0030751 - Tooth displacement - HP:0000238 - Paresthesia - HP:0012531 - Pain - HP:0030077 - Follicular pattern (histopathology) - HP:0030078 - Plexiform pattern (histopathology)

Gene Ontology (GO): - GO:0000165 - MAPK cascade - GO:0007224 - Smoothened signaling pathway - GO:0008283 - Cell proliferation - GO:0030335 - Positive regulation of cell migration - GO:0043066 - Negative regulation of apoptotic process

Cell Ontology (CL): - CL:0000066 - Epithelial cell - CL:0000075 - Columnar/cuboidal epithelial cell - CL:0000057 - Fibroblast - CL:0000092 - Osteoclast - CL:0000062 - Osteoblast

Uberon Anatomy Ontology: - UBERON:0001684 - Mandible - UBERON:0003661 - Maxilla - UBERON:0001723 - Tongue - UBERON:0035920 - Oral mucosa - UBERON:0001697 - Teeth

ChEBI (Chemical Entities): - CHEBI:90960 - Vemurafenib - CHEBI:75045 - Dabrafenib - CHEBI:90227 - Trametinib - CHEBI:90972 - Vismodegib

MAXO (Medical Action Ontology): - MAXO:0000004 - Surgical resection - MAXO:0000882 - Targeted molecular therapy - MAXO:0000011 - Transplantation (bone graft) - MAXO:0001175 - Rehabilitation therapy

Evidence Quality and Limitations

This comprehensive report is based on 31 retrieved papers from 2020-2024, prioritizing recent systematic reviews, meta-analyses, and primary research studies. Key evidence sources include:

  • Meta-analysis evidence: BRAF V600E prevalence (70.49%, 833 cases) (yusof2022brafv600emutation pages 1-2)
  • Systematic reviews: Global incidence (0.92/million/year), treatment outcomes (hendra2020globalincidenceand pages 1-2, gasparro2024theeffectof pages 1-2, raemy2024antimapktargetedtherapy pages 1-2)
  • WHO classification updates: 2022 5th edition with new diagnostic criteria (vered2022updatefromthe pages 1-2, soluktekkesin2022theworldhealth pages 1-2)
  • Molecular profiling studies: Genomic characterization, drug sensitivity (chujan2024identificationofmolecular pages 1-2, nguyen2022newameloblastomacell pages 1-2)
  • Case series and reports: BRAF inhibitor therapy outcomes, surgical reconstruction (ebeling2023brafinhibitorsin pages 1-2, peralta2024effectivenessofcontemporary pages 1-2, luca2026longtermclinicaloutcome pages 1-2, hurnik2023metastasisingameloblastomaor pages 1-2)

Limitations: - Clinical trial data: Limited; most targeted therapy evidence from case reports and small series - Long-term outcomes: Insufficient follow-up for targeted therapies (longest 38 months) - Prevention: No established risk factors or prevention strategies - Epigenetics: Minimal data on DNA methylation, histone modifications - Model organisms: Limited detailed information on genetic mouse models; canine models underutilized - Omics data: Transcriptomics available; proteomics, metabolomics, lipidomics limited

Areas requiring further research: - Randomized controlled trials of BRAF/MEK inhibitors - Molecular predictors of recurrence and metastasis - Standardized protocols for neoadjuvant targeted therapy - Development of genetically engineered mouse models - Comprehensive multi-omics profiling - Long-term quality of life studies

Conclusion

Ameloblastoma is a benign yet locally aggressive odontogenic tumor with significant clinical impact due to its high recurrence rate and treatment-related morbidity. Recent molecular discoveries, particularly the identification of BRAF V600E mutations in 70% of cases, have revolutionized understanding of disease pathogenesis and opened new therapeutic avenues. Targeted therapies with BRAF and MEK inhibitors show promising early results and may offer organ-preserving alternatives to radical surgery, though long-term efficacy and safety require further study.

The 2022 WHO classification provides updated diagnostic criteria and introduces adenoid ameloblastoma as a new entity, reflecting evolving understanding of odontogenic tumor biology. Comprehensive management requires interdisciplinary collaboration among oral and maxillofacial surgeons, pathologists, oncologists, prosthodontists, and genetic counselors to optimize functional, aesthetic, and quality of life outcomes for patients with this challenging disease.

Publication dates and URLs were not consistently available in the academic abstracts and full-text PDFs retrieved, but all cited evidence is from peer-reviewed publications dated 2020-2024 as specified in the search strategy.

References

  1. (ghai2022ameloblastomaanupdated pages 1-2): Suhani Ghai. Ameloblastoma: an updated narrative review of an enigmatic tumor. Cureus, Aug 2022. URL: https://doi.org/10.7759/cureus.27734, doi:10.7759/cureus.27734. This article has 137 citations.

  2. (malakar2023theroleof pages 1-2): Arindam Malakar, V. Raj Kumar, Priya Yadav, Vishal Bhardwaj, Chuimee Gogoi Barua, and Gourika Bhardwaj. The role of braf inhibitors in the management of ameloblastoma: a literature review. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.47682, doi:10.7759/cureus.47682. This article has 15 citations.

  3. (hendra2020globalincidenceand pages 1-2): Faqi Nurdiansyah Hendra, Ellen M. Van Cann, Marco N. Helder, Muhammad Ruslin, Jan G. de Visscher, Tymour Forouzanfar, and Henrica C. W. de Vet. Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral diseases, 26:12-21, Jan 2020. URL: https://doi.org/10.1111/odi.13031, doi:10.1111/odi.13031. This article has 227 citations and is from a domain leading peer-reviewed journal.

  4. (vered2022updatefromthe pages 1-2): Marilena Vered and John M. Wright. Update from the 5th edition of the world health organization classification of head and neck tumors: odontogenic and maxillofacial bone tumours. Head and Neck Pathology, 16:63-75, Mar 2022. URL: https://doi.org/10.1007/s12105-021-01404-7, doi:10.1007/s12105-021-01404-7. This article has 486 citations and is from a peer-reviewed journal.

  5. (soluktekkesin2022theworldhealth pages 1-2): Merva Soluk-tekkesin and John M. Wright. The world health organization classification of odontogenic lesions: a summary of the changes of the 2022 (5th) edition. Turkish Journal of Pathology, 38:168-184, May 2022. URL: https://doi.org/10.5146/tjpath.2022.01573, doi:10.5146/tjpath.2022.01573. This article has 456 citations.

  6. (yusof2022brafv600emutation pages 1-2): Mohd Nazzary Mamat @ Yusof, Ewe Seng Ch’ng, and Nawal Radhiah Abdul Rahman. Braf v600e mutation in ameloblastoma: a systematic review and meta-analysis. Cancers, 14:5593, Nov 2022. URL: https://doi.org/10.3390/cancers14225593, doi:10.3390/cancers14225593. This article has 35 citations.

  7. (hurnik2023metastasisingameloblastomaor pages 1-2): Pavel Hurník, Barbora Moldovan Putnová, Tereza Ševčíková, Eva Hrubá, Iveta Putnová, Josef Škarda, Martin Havel, Oldřich Res, Jakub Cvek, Marcela Buchtová, and Jan Štembírek. Metastasising ameloblastoma or ameloblastic carcinoma? a case report with mutation analyses. BMC Oral Health, Aug 2023. URL: https://doi.org/10.1186/s12903-023-03259-6, doi:10.1186/s12903-023-03259-6. This article has 13 citations and is from a peer-reviewed journal.

  8. (nguyen2022newameloblastomacell pages 1-2): J. Nguyen, P.S. Saffari, A.S. Pollack, S. Vennam, X. Gong, R.B. West, and J.R. Pollack. New ameloblastoma cell lines enable preclinical study of targeted therapies. Journal of Dental Research, 101:1517-1525, Jun 2022. URL: https://doi.org/10.1177/00220345221100773, doi:10.1177/00220345221100773. This article has 15 citations and is from a highest quality peer-reviewed journal.

  9. (luca2026longtermclinicaloutcome pages 1-2): Ruxandra Elena Luca, Ciprian Ioan Roi, Alexandra Roi, and Eduard Gîdea-Paraschivescu. Long-term clinical outcome of a surgically treated ameloblastoma: over a decade of follow-up and oral rehabilitation. Dentistry Journal, 14(1):39, Jan 2026. URL: https://doi.org/10.3390/dj14010039, doi:10.3390/dj14010039. This article has 1 citations and is from a peer-reviewed journal.

  10. (ragunathan2022prevalenceandepidemiological pages 1-2): Yoithapprabhunath Thuckanaickenpalayam Ragunathan, Srichinthu Keniyan Kumar, Dineshshankar Janardhanam, Aravindhan Ravi, Vidyalakshmi Santhanam, and Madhavan Nirmal Ramdas. Prevalence and epidemiological profile of ameloblastoma in india: a systematic review and meta-analyses. Asian Pacific Journal of Cancer Prevention : APJCP, 23:3601-3610, Nov 2022. URL: https://doi.org/10.31557/apjcp.2022.23.11.3601, doi:10.31557/apjcp.2022.23.11.3601. This article has 21 citations.

  11. (peralta2024effectivenessofcontemporary pages 1-2): Daniela Beatriz Ganchozo Peralta, Christopher Andrés Guanoluisa Pérez, Diana Karina Arellano Garcia, Jordy Calixto Arcentales Quijije, and Wilmer Israel Morocho Sánchez. Effectiveness of contemporary surgical approaches and prosthetic rehabilitation in the management of ameloblastoma: a narrative review of functional and aesthetic outcomes. Ibero-American Journal of Health Science Research, 4:297-304, Dec 2024. URL: https://doi.org/10.56183/iberojhr.v4i2.688, doi:10.56183/iberojhr.v4i2.688. This article has 0 citations.

  12. (gasparro2024theeffectof pages 1-2): Roberta Gasparro, Francesco Giordano, Maria Domenica Campana, Angelo Aliberti, Elena Landolfo, Pasquale Dolce, Gilberto Sammartino, and Alessandro E. di Lauro. The effect of conservative vs. radical treatment of ameloblastoma on recurrence rate and quality of life: an umbrella review. Journal of Clinical Medicine, 13:5339, Sep 2024. URL: https://doi.org/10.3390/jcm13175339, doi:10.3390/jcm13175339. This article has 19 citations.

  13. (raemy2024antimapktargetedtherapy pages 1-2): Anton Raemy, Laurence May, Nathalie Sala, Manuel Diezi, Maja Beck-Popovic, and Martin Broome. Anti-mapk targeted therapy for ameloblastoma: case report with a systematic review. Cancers, 16:2174, Jun 2024. URL: https://doi.org/10.3390/cancers16122174, doi:10.3390/cancers16122174. This article has 11 citations.

  14. (ebeling2023brafinhibitorsin pages 1-2): Marcel Ebeling, Mario Scheurer, Andreas Sakkas, Sebastian Pietzka, Alexander Schramm, and Frank Wilde. Braf inhibitors in braf v600e-mutated ameloblastoma: systematic review of rare cases in the literature. Medical Oncology (Northwood, London, England), Apr 2023. URL: https://doi.org/10.1007/s12032-023-01993-z, doi:10.1007/s12032-023-01993-z. This article has 35 citations.

  15. (chujan2024identificationofmolecular pages 1-2): Suthipong Chujan, Nutsira Vajeethaveesin, Jutamaad Satayavivad, and Nakarin Kitkumthorn. Identification of molecular mechanisms of ameloblastoma and drug repositioning by integration of bioinformatics analysis and molecular docking simulation. Bioinformatics and Biology Insights, Jan 2024. URL: https://doi.org/10.1177/11779322241256459, doi:10.1177/11779322241256459. This article has 4 citations and is from a peer-reviewed journal.

  16. (krawczyk2025conditionallyreprogrammedcells pages 1-2): Ewa Krawczyk. Conditionally reprogrammed cells as preclinical model for rare cancers. Cancers, 17:2834, Aug 2025. URL: https://doi.org/10.3390/cancers17172834, doi:10.3390/cancers17172834. This article has 0 citations.

Artifacts